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Abstract: 
p53 in Cerebellar Development, Medulloblastoma 
Initiation, and Treatment Resistance 
 
by Daniel Treisman 
 
TP53 is a crucial tumor suppressor inactivated in the majority of human cancers. 
Medulloblastoma (MB), the most common malignant pediatric brain tumor, is an 
exception, rarely mutating TP53. Within the Sonic Hedgehog (SHH) MB subtype, TP53 
mutation is a prognostic factor, and mutant TP53 SHH-MBs have the worst prognosis of 
all subtypes. How most SHH-MBs can form without mutating TP53 remains unclear. 
Almost all SHH-MBs with TP53 mutation arise during childhood, indicating that 
mutation to TP53 must occur during a limited developmental window. Early postnatal 
(postnatal day 0.5) granule cell precursors (GCPs) are p53-activation resistant following 
genotoxic stress, whereas late postnatal (postnatal day 10) GCPs are p53-activation 
sensitive. I hypothesize that a p53-activation resistant GCP population gives rise to p53 
wild type SHH-MBs and that p53-activation sensitive GCPs are eliminated during 
postnatal development unless they harbor mutant p53.  
Using two mutant p53 alleles, a conditional knockout, p53∆E5-6, and a hypomorph, 
p53R172P, I demonstrated that p53 activation occurs during cerebellar development, and is 
activated in the earliest detectable lesions driven by Ptch1 loss. Consistently, p53-
dependent apoptosis plays a major role in both the initiation and progression of SHH-
MBs, while p53-dependent cell cycle arrest only delays SHH-MB progression. 
Surprisingly, a subset of Ptch1-deficient pre-neoplastic lesions (PNLs) showed no 
 viii 
evidence of p53 activation, regardless of p53 mutation, providing a mechanistic basis for 
the formation of p53 wild type (WT) SHH-MBs. To test whether these PNL represented a 
p53-activation resistant population, I designed a clinically relevant treatment scheme to 
induce genotoxic stress and elicit a heightened p53 response.  I found that treatment 
eliminated all PNL cells and reduced the incidence of SHH-MBs, but only when p53-
mediated apoptosis was activated. Activation of p53-mediated cell-cycle arrest alone 
halted proliferation and induced neuronal differentiation, but failed to eliminate Sox2-
positive stem-like cells, which were capable of surviving treatment and generating highly 
proliferative SHH-MB. Thus, only when p53 activation surpasses a critical threshold will 
Sox2-positive stem-like cells be eliminated, preventing p53 recurrence and determining 
therapeutic outcomes. 
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Chapter I: Introduction 
1.1 A connection between p53 and SHH-medulloblastoma  
Tumor suppressor TP53 is one of the most frequently targeted pathways in 
cancers, with approximately 50% showing alterations to TP53 (Joerger and Fersht 2016). 
Curiously, many pediatric brain tumors, including medulloblastoma (MB) and low-grade 
glioma, the most common malignant and benign pediatric brain tumor types, respectively, 
rarely harbor mutations to TP53 (Adesina et. al., 1994). In spite of the scarcity of TP53 
mutation, MB incidence is increased in individuals with Li-Fraumeni, the TP53-
associated hereditary cancer predisposition syndrome (Northcott et. al., 2012, Kool et. al., 
2014). Recent studies have divided MBs into several genetic subtypes, including a 
subtype linked to the Sonic Hedgehog (SHH) signaling pathway (Thompson et. al., 
2006). Li-Fraumeni syndrome is exclusively associated with the SHH-MB subtype, and 
mutation of TP53 is one of the chief prognostic indicators, with mutant TP53 showing a 
strong correlation with treatment-resistant disease and poor survival (Zhukova et. al., 
2013). Mutation of TP53 is associated with development of aggressive, treatment-
resistant MBs in the SHH subgroup (Tabori et. al., 2010, Zhukova et. al., 2013). It 
remains unclear what role TP53 plays in preventing the initiation of MBs (Gajjar and 
Robinson 2014). One of the remaining questions in the field is how many SHH-MBs 
form without requiring TP53 mutation, and, as a corollary, the role that TP53 plays 
during MB initiation. 
This discrepancy may be explained by differential p53 response in stem and 
precursor populations found in the developing cerebellum (Pazzaglia et. al., 2006, Yang 
et. al., 2008). As a pediatric tumor, SHH-MB cell of origin has been identified as 
belonging to the neuroectodermal lineage, including granule cell precursors (GCPs) of 
the embryonic and postnatal cerebellum (Marino et. al., 2000, Yang et. al., 2008, Sutter 
et. al., 2010). Treatment of GCPs with radiation during cerebellar development reveals 
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differential radiation response from embryonic and early postnatal (postnatal day 0.5) 
GCPs, which do not activate p53 following irradiation stress, to late postnatal GCPs 
(postnatal day 10), which respond to radiation stress by inducing p53 activation and 
apoptosis (Pazzaglia et. al., 2006, Tanori et. al., 2013). One interpretation of this data 
supports the existence of two types of GCPs, a population resistant to the activation of 
p53 following stress and a population that is sensitive to stress signals and activates p53 
following oncogenic signaling or genotoxic stress. I hypothesize that p53-activation 
resistant GCPs are capable of giving rise to SHH-MBs retaining a functional p53 
pathway, while those GCPs p53-activation sensitive would be eliminated during 
development unless they had mutated p53, either at the germline or prior to early 
postnatal development.  
To address this hypothesis, I developed a three-tiered approach to assess p53 
function, utilizing: 1) a fully functional p53 allele, 2) a hypomorph allele, p53R172P 
capable of reduced activation of a subset of effectors, primarily cell cycle arrest 
associated, and no activation of apoptotic effectors, and 3) a conditionally inactive p53 
allele, p53∆E5-6, that can serve as a marker of p53 activation (Liu et. al., 2004, Wang et. 
al., 2009). Using p53∆E5-6 as a marker overcomes several of the constraints preventing 
investigation of p53 in developmental populations, allowing accumulation of p53 by 
eliminating the p53-MDM2 negative feedback loop and preventing the removal of cells 
that would normally be eliminated by p53-mediated apoptosis (Wang et. al., 2009). The 
p53R172P allele restores partial p53 function, thereby demonstrating the result of functional 
p53 activity while still preventing the elimination of stressed cells (Liu et. al., 2004). By 
placing these p53 mutant alleles into the context of the SHH-MB model subtype the well-
characterized Ptch1+/- genetically engineered mouse model (Goodrich et. al., 1997, 
Wetmore et. al., 2001), and recombining p53∆E5-6 in the brain with hGFAP-Cre (Zhuo et. 
al. 2001), I was able to develop a model capable of testing the activation of p53 activation 
in cerebellar development and MB initiation. 
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1.2 MB Epidemiology and Pathology 
MB is an aggressive, malignant pediatric tumor arising from the neuroepithelial 
lineage of the cerebellum (Louis et. al., 2007). MB is primarily a pediatric disease, with 
70% of MBs arising in infants and children (Louis et. al., 2007). MBs occur in 0.5 per 
100,000 children, and 0.058 per 100,000 in adults (Giordana et. al., 1999, Louis et. al., 
2007, Gajjar and Robinson 2014). MBs are typically responsive to combined therapy, 
which includes surgery, radiation and chemotherapy in individuals older than 3, and 
chemotherapy and surgery without radiation in infants (Thompson et. al., 1999, 
Lewandowicz et. al., 2000, Louis et. al., 2007, Crawford et. al., 2007). Based on the 
quality of surgical resection and the presence of metastatic spread upon initial diagnosis, 
MBs are divided into average- and high- risk patients.  Treatment is effective in 70-80% 
of average risk MB patients, leading to survival with no recurrent disease (Crawford et. 
al., 2007). Treatment of MBs in infants is less successful, with average survival of 40%, 
primarily due to the inability to safely use radiation (Crawford et. al., 2007). Due to the 
harsh nature of these treatments on developing brain, innovation of therapies capable of 
targeting the tumor without incurring as great an effect on healthy tissues remains an area 
of interest in MB research. Pediatric patients treated with a standard radiation dose often 
suffer a gradual decline in IQ following treatment, with an estimated decline of 20 IQ 
points in patients younger than 8 years of age (Palmer et. al., 2013, Merchant et. al., 
2014, Moxon-Emre et. al., 2014). Thus, translational research for MBs pursue three 
objectives – predicting which MBs are likely to respond to standard therapy and which 
are resistant, reducing the side effects associated with modern treatment strategies, and 
finding a targeted therapy capable of eliminating treatment-resistant MBs.  
Several strategies have been developed to diagnose MBs and assess tumor 
severity. All MBs share some diagnostic characteristics: they are generally comprised of 
densely packed cells with large nuclei and relatively little cytoplasm, and they typically 
arise in the cerebellar vermis and fourth ventricle of pediatric patients (Eberhart and 
Berger 2003, Louis et. al., 2007, Rodriguez et. al., 2007). Immunological markers 
associated with MBs fall into several categories, including neural markers 
Synaptophysin, considered the characteristic marker for MB, Neurofilament (NF) and 
4 
Paired Box Gene 6 (Pax6); neuroepithelial precursor marker Nestin; glial marker Glial 
Fibrillary Acidic Protein (GFAP); and Retinal S-antigen, marking retinal features 
(Schwechheimer et. al., 1987, Louis et. al., 2007). Other characteristic markers detected 
in MBs include the zinc-finger protein Zic1, a transcription factor associated with granule 
cell precursors, and neurotrophin receptor TrkC, associated with desmoplastic MBs, with 
frequent immunostaining in 70% and 40% of MBs, respectively (Segal et. al., 1994, 
Yokota et. al., 1996, Aruga et. al, 1998, Louis et. al., 2007). MBs are traditionally 
classified through histopathology, dividing MBs into 5 histological subtypes: classic, 
desmoplastic, MBEN (medulloblastoma with extensive nodularity and advanced neuronal 
differentiation), large cell and anaplastic (Louis et. al., 2007). Of these histological 
groups, MBEN and desmoplastic are often combined into a single group referred to as 
D/N, and the large cell and anaplastic histology is typically describer as LC/A.  
Classical MBs, the most common histological variant, account for 73% of 
pediatric MBs, and are identified by the presence of rounded cells featuring large, darkly 
stained nuclei and little cytoplasm, as well as cells arranged into palisades or Homer-
Wright rosettes (Louis et. al., 2007, Gajjar and Robinson 2014). Desmoplastic MBs are 
identified by the pattern of dense, hyper-chromatic cellular regions surrounding 
eosinophilic nodes, which contain cells at a lower density (Louis et. al., 2007, Gajjar and 
Robinson 2014). The distinguishing feature of the MBEN subtype is the presence of 
large, irregular nodes and increased neuronal differentiation of cells within the nodes 
(Louis et. al., 2007). Staining for a reticulin matrix in the internodular regions is an 
additional identifier of these subtypes. Additionally, desmoplastic and MBEN subtypes, 
although only accounting for 10.3% of overall pediatric MBs, occur predominantly 
within infants, accounting for 57% of infant MBs (Ellison 2010). Anaplastic MBs are 
characterized by pleomorphic nuclei, frequent nuclear molding and high mitotic 
frequency (Louis et. al., 2007). Large cell MBs, although often sharing traits with 
anaplastic MB, are distinguished by the presence of cells with large nuclei, typically 3-4 
fold larger (Louis et. al., 2007). MBs exclusively containing large cell histology are rare, 
instead featuring clusters of large cells surrounded by dense anaplastic cell populations 
(Louis et. al., 2007). When the anaplastic and large cell MB subtypes are combined into 
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the LC/A subtype, they account for 16.6% of pediatric MBs with comparable frequency 
in infant and childhood MBs (Ellison 2010). The histological classification system of 
MBs provides few prognostic indicators. Within infant populations, desmoplastic tumors 
show the best prognosis, with typical survival of 60% versus 20-40% for non-
desmoplastic MBs (Crawford et. al., 2007). The presence of large cell and anaplastic 
morphology has been suggested as an indication of aggressive tumors with poor 
prognosis, although this association has not been consistently supported (Louis et. al., 
2007, Zhukova et. al., 2013).  
1.3 Hereditary Predisposition Syndromes Contributing to MB Incidence 
Observation of the epidemiology of MBs led to the discovery that several 
hereditary cancer predisposition syndromes were capable of contributing to the incidence 
of MB. Two of these syndromes, Gorlin Syndrome (or Nevoid Basal Cell Carcinoma 
Syndrome, NBCCS) and Turcot syndrome, are associated with critical signaling 
pathways involved in cerebellar development, while the third is Li-Fraumeni syndrome, 
associated with germline alteration of TP53 (Rossi et. al., 2008, Louis et. al., 2007, Gajjar 
and Robinson 2014).  
Gorlin Syndrome, initially described in 1960, is an autosomal dominant disorder 
associated with basal cell carcinomas and MBs, as well as bone cysts in the mandible, 
macrocephaly, and several other physiological defects (Gorlin and Goltz 1960, Kimonis 
et. al., 1997). Between 3-5% of Gorlin syndrome patients will be diagnosed with MBs, 
with the majority arising during infancy (Garré et. al., 2009). Gorlin syndrome has been 
linked to inactivating mutations of two genes, patched (PTCH1) or suppressor of fused 
(SUFU), thereby leading to activation of Hedgehog signaling pathway (Jiang and Hui 
2008). Although mutations in SUFU only represent a small fraction of the overall 
Gorlin’s population, the frequency of MBs within these patients is approximately 20 
times greater than that seen with PTCH1 (Smith et. al., 2014). Sporadic mutation of the 
Hedgehog pathway genes is also often observed within MBs, with approximately 9% of 
MBs bearing a sporadic mutation in PTCH1. The majority of tumors with a sporadic 
mutation in PTCH1 are found to not retain the wild type PTCH1 allele, indicating that 
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complete loss provides elevated Hedgehog pathway activation, the oncogenic driver in 
SHH-MBs (Pazzaglia et. al., 2002, Ward et. al., 2009, Read et. al., 2009, Tamayo-Orrego 
et. al., 2016). 
Like Gorlin Syndrome, Turcot syndrome is a well-characterized but rare 
hereditary condition initially discovered in families displaying an overabundance of 
intestinal polyps, leading to heightened incidence of colon cancer, as well as increased 
risk of gliomas and MBs (Huang et. al., 2000). Overall MB incidence in Turcot patients 
is at least 100 fold greater than the general population, although incidence is still less than 
1%. Turcot syndrome is associated with mutations in adenomatous polyposis coli (APC), 
leading to activation of the Wingless (Wnt) pathway (Huang et. al., 2000, Clevers 2006). 
Wnt is a ligand capable of interacting with a complex comprised of the transmembrane 
protein Frizzled and LRP5/6, which in turn activates Disheveled to inhibit the APC 
complex (Clevers 2006). Inhibition of the APC complex allows transport of ß-Catenin to 
the nucleus, where ß-Catenin then forms a complex with TCF/LEF to allow transcription 
of the Wnt pathway target genes, including several genes involved in proliferation and 
inhibition of apoptosis, such as c-Myc and CCND1 (Clevers 2006). Several studies have 
demonstrated that mutations of CTNNB1, the gene associated with ß-catenin, are present 
in approximately 8% of MBs, accounting for approximately 90% of sporadic Wnt 
pathway mutations, though mutations to AXIN1, the APC complex backbone, and APC 
account for 3% and 2% of Wnt pathway mutations, respectively (Baeza et. al., 2003).  
Li-Fraumeni syndrome is a rare autosomal dominant genetic condition 
characterized by mutations in the p53 pathway, with between 60-80% resulting from 
mutations in TP53 (Adesina et. al., 1994). Mutations in TP53 typically prevent 
transcription factor activity by interfering with the p53 DNA binding domain, a region of 
the TP53 allele associated with 90% of TP53 mutations, including all six of the 
mutational hotspots (Joerger and Fersht 2016). Due to the importance of p53 in 
preventing neoplastic transformation, the lifetime risk of developing cancer in Li-
Fraumeni patients is 73% in men and 100% in women (Wu et. al., 2006). Soft-tissue 
sarcomas are the most frequent tumor associated with Li-Fraumeni, though a wide range 
of tumor varieties, including myeloid lymphoma, leukemia, non-small cell lung cancer, 
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breast cancer, astrocytoma, and MB, occur with increased frequency in this population 
(Wu et. al., 2006). Genetic analysis of MBs found that mutation of TP53 only occurred 
within 8-10% of the total cases (Adesina et. al., 1994, Louis et. al., 2007, Tabori et. al., 
2010). Curiously, although the majority of tumors containing mutant TP53 also saw loss 
of chromosome 17p, the frequency of 17p loss extends far beyond those tumors with 
mutant TP53, indicating that TP53 may not be the only gene targeted by loss of 
chromosome 17p (Cho et. al., 2010). The scarcity of TP53/p53 mutations in MBs 
represents an exception to the observed trend in other cancers that has not been fully 
explored, but may provide insight into cerebellar development and the cellular origin of 
MBs (Wetmore et. al., 2001, Tamayo-Orrego et. al., 2016). 
1.4 Molecular Subgroups of MB  
The clear association between several signaling pathways and MB occurrence 
suggests that prognosis and expected treatment response could be predicted with a 
method of molecular categorization of MB. In 2006, a collaborative effort headed by the 
Gilbertson lab performed expression profiling, using 46 pediatric MB samples, 
identifying five genetic subtypes (Thompson et. al., 2006, Robinson et. al., 2012, Jones 
et. al., 2012). Two of these subtypes were found to correspond with developmental 
pathways of the cerebellum, Hedgehog and Wnt, with the other three subgroups not 
explicitly matching with any known signaling pathway (Thompson et. al., 2006). This 
was explored by subsequent studies, which, using a broader range of samples and 
techniques, condensed the number of subgroups to 4, retaining the SHH and Wnt groups, 
but also proposing that Group 3 MB were associated most strongly with c-Myc activation 
(Northcott et. al., 2010). Based on these molecular varieties, new approaches to diagnosis 
and deeper insight into MB prognosis have become available. 
Only 10% of the total diagnosed MBs are characterized as the Wnt subgroup, 
associated with 90% patient survival, the best overall prognosis amongst MB subtypes 
(Louis et. al., 2007). Wnt MBs occur primarily in children and young adults, and almost 
never in infants (Shih et. al., 2014). Several mutations are enriched within the Wnt 
subgroup, with nearly all MBs of this subtype carrying mutations within CTNNB1, the 
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gene encoding ß-Catenin, as well as several other genes enhancing Wnt pathway 
activation, such as methyltransferase KMT2D and helicase SMARCA4 (Gajjar and 
Robinson et. al., 2014). Additionally, these tumors tend to show elevated c-Myc 
expression. Although sporadic TP53 mutations are associated with 10-15% of Wnt MBs, 
overall survival does not appear to change between TP53 wild type and TP53 mutant 
tumors (Pfaff et. al., 2010, Jones et. al., 2012). Due to excellent prognosis and reliable 
treatment response, the Wnt subgroup has not been a typical focus for translational 
research.  
Group 3 (Group C) MBs, accounting for approximately 25% of MB, are regarded 
as the most aggressive subgroup, with only 50% overall survival in group 3 patients 
(Northcott et. al., 2010, Korshunov et. al., 2012, Jones et. al., 2012, Zhukova et. al., 
2013). Group 3 MBs are highly aggressive, with metastasis in approximately 40% of 
patients, and occur primarily in infants and young children (Northcott et. al., 2010, Shih 
et. al., 2014). Group 3 MBs, while not linked to any hereditary syndrome, exhibit 
increased expression of MYC in the majority of samples, as well as amplification of the 
MYC oncogene in approximately 16% of tumors (Cho et. al., 2011, Northcott et. al., 
2012). In addition to MYC, TGF-ß receptor pathway genes undergo copy number 
alterations in 20.2% of all Group 3 MBs (Cho et. al., 2011, Northcott et. al., 2012, Gajjar 
and Robinson et. al., 2014). Other than these alterations, a wide variety of chromatin 
modifying genes, such as SMARCA4, KMT2D, CHD7 and several members of the KDM 
family, are altered in Group 3 MBs (Cho et. al., 2011, Northcott et. al., 2012). Group 3 
MBs possessing MYC amplification represent the most severe of all MBs, with an overall 
survival rate of 21%, compared to 75% overall survival in Group 3 MBs without MYC 
amplification (Cho et. al., 2011). Group 3 MBs have been of great interest clinically, as 
this subtype has some of the worst prognosis, leading to development of c-Myc driven 
mouse models (Pei et. al., 2012, Kawauci et. al., 2012).  
Group 4 MBs are the most common subgroup, representing 35% of diagnosed 
MBs and predominantly occurring in children greater than 3 years of age and adults 
(Louis et. al., 2007, Gajjar and Robinson 2014). Group 4 MBs typically respond well to 
therapy, with a 75% overall survival rate (Shih et. al., 2014). Evidence exists that these 
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tumors are potentially driven by a sex-linked gene, as tumor incidence is three times 
greater in males, and female patients often show loss of the X-chromosome (Cho et. al., 
2011, Gajjar and Robinson 2014). Group 3 and Group 4 MBs possess molecular 
similarities, as demonstrated by their overlapping expression pattern, and it has been 
proposed that Group 3 and Group 4 represent a GABAergic and glutamatergic neuron-
like subtype, respectively, with some portion of these tumors carrying a mixed expression 
pattern (Robinson et. al., 2012, Cho et. al., 2011). Likewise, many molecular alterations 
observed in Group 4 MBs overlap with Group 3 MBs, including alterations to SMARCA4 
and KMT2D (Northcott et. al., 2010, Gajjar and Robinson 2014). Mutation of TP53 is 
very rare in Group 4 and non-existent in Group 3, although isochrome 17q is a very 
common phenomenon (Cho et. al., 2011). Due to the lack of a central molecular 
mechanism, a representative mouse model for Group 4 MBs has yet to be developed. 
The best studied of the MB subgroups is the SHH-MB. SHH-MBs, accounting for 
25-30% of MBs, are associated with mutations affecting components of the hedgehog 
pathway. Approximately 30% of these tumors carry mutations in PTCH1, while other 
tumors of this subtype increased Hedgehog pathway signaling by altering other pathway 
components, including Smoothened (SMO) or Suppressor of Fused (SUFU), or by 
amplification of downstream targets, most frequently Gli1, Gli2 or n-MYC (Gajjar and 
Robinson 2014, Shih et. al., 2014). Likewise, loss of chromosome 9q, corresponding with 
the location of PTCH1, is observed in approximately 45% of SHH-MBs and is enriched 
in tumors possessing mutation to one allele of PTCH1, occurring in approximately 90% 
of patients with PTCH1 mutation (Cho et. al., 2011). As a result of the frequency of 
deregulated hedgehog signaling, one of the key treatment interests for SHH-MBs is the 
introduction of potent Hedgehog pathway inhibitors, preferably capable of targeting the 
downstream hedgehog pathway targets.  
The potential for targeting the Hedgehog pathway was recognized even before the 
current molecular categories were discovered. Using the theoretical model of oncogene 
addiction, it was hypothesized that disruption of the Hedgehog pathway would target a 
vulnerability in SHH-MBs. Initial trials made use of cyclopamine, a naturally occurring 
inhibitor of Smo extracted from the corn lily, and were able to demonstrate that hedgehog 
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pathway blockade was capable of inducing growth arrest in both human cell line and 
murine models (Berman et. al., 2002, Romer et. al., 2004). Although largely successful, 
clinical trials with vismodegib, an early Smo inhibitor, showed that a patient with a 
metastatic SHH-MB developed resistance to the Hedgehog pathway inhibitor within three 
months of therapy, by acquiring a single point mutation to Smo (Yauch et. al., 2009). 
Additional Hedgehog pathway inhibitors with the ability to target components further 
down the Hedgehog pathway, such as Gli1/2, have been developed, which may prove 
valuable in treating SHH-MBs with amplifications of downstream Hedgehog pathway 
components (Yauch et. al., 2009, Kim et. al., 2013). While several potential compounds 
have been discovered that fit this criteria, none have gone beyond clinical trials, although 
arsenic trioxide, a potent inhibitor of SHH effectors Gli1 and Gli2, shows potent 
inhibition of MB progression in vivo (Kim et. al., 2013).  
TP53 alterations are most common in the SHH-MB subgroup (Zhukova et. al., 
2013). Approximately 20% of SHH-MBs harbor mutations in TP53 (Eberhart et. al., 
2005, Tabori et. al., 2010, Jones et. al., 2012). Of these mutations, roughly half are 
germline, representing the majority of those MBs that occur within Li-Fraumeni 
syndrome patients. Based on molecular characterization of the TP53 mutant SHH-MBs, 
distinct mutation and chromosomal alterations become evident. Perhaps the most 
unexpected observation from these tumors is that less than 1% of MBs possess mutations 
to both TP53 and PTCH1 (Parsons et. al., 2011). The correlation between mutations to 
these genes was explored using a Math1-promoter associated sleeping beauty transposon, 
thereby leading to insertional mutagenesis within the Math1+ granule cell precursor 
population (Wu et. al., 2012). The sleeping beauty system was used in Ptch1+/- or p53-/- 
models, and insertion sites associated with decreased tumor latency were assessed (Wu 
et. al., 2012). Curiously, although the mutation most associated with sleeping beauty in 
the p53-/- background was Ptch1, mice in the Ptch1+/- background never showed mutation 
in p53 (Wu et. al., 2012). Likewise, TP53 mutant tumors frequently undergo 
chromosome 17p loss, but almost never correspond with loss of chromosome 9q, the 
location of PTCH1 (Cho et. al., 2011). Analysis of allele frequency and single nucleotide 
variant (SNV) accumulation demonstrated that SHH-MBs could be segregated based on 
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TP53 mutational status, with MBs containing mutant TP53 typically occurring during late 
childhood and containing several fold greater SNVs as well as evidence of 
chromothripsis, widespread chromosomal rearrangement arising from a single event 
(Rausch et. al., 2012, Jones et. al., 2012). Unlike the Wnt subtype, TP53 mutations are a 
prognostic indicator within the SHH-MB subgroup, with a strong association between 
mutant TP53 and rapid progression. Initial reports indicated that presence of mutant TP53 
was sufficient to induce complete treatment resistance and rapid lethality, with 100% 
fatality within 2 years as opposed to 74% survival within p53 wild type, with subsequent 
reports demonstrating comparable associated risk, albeit with lower overall severity, 
demonstrating survival in 41% of TP53 mutant MBs compared to 81% TP53 wild type. 
Activation of p53 in murine models by treatment with MDM2 inhibitor Nutlin-3 was able 
to suppress the rate of MB growth in xenograft models, but was insufficient to prevent 
tumor formation (Künkele et. al., 2012). The correlation between poor prognosis and 
TP53 mutation has served to highlight the need for new therapeutic approaches capable 
of targeting TP53-mutant SHH-MB.  
1.5 The TP53 Signaling Pathway 
TP53 and its associated pathway is one of the most important and well-studied 
tumor suppressor responses available to regulate abnormal cell populations. First 
discovered in 1979, p53 was initially believed to be a viral oncogene carried by SV40.  
(Kress et. al., 1979, Lane and Crawford 1979, Linzer and Levine 1979, [reviewed in 
Soussi 2010]). It was later theorized that, although TP53 was enriched in cells infected 
with the SV40 virus, the newly discovered TP53 was in fact an oncogene, a belief 
fostered by the frequency of enrichment within tumor cells and the potential of 
transfected TP53 along with the KRAS oncogene, to induce the formation of tumors 
within transfected cells (Parada et. al., 1984, Jenkins et. al., 1984, Eliyahu  et. al., 1984). 
Understanding of TP53 took a radical change in 1989, when it was demonstrated that, 
when non-mutant p53 was cloned, no oncogenic function was detected. Rather, the 
majority of TP53 detected in tumor was demonstrated to harbor mutations rendering the 
gene non-functional (Finlay et. al., 1989, Baker et. al., 1989, Takahashi et. al., 1989). 
This discovery was followed shortly by the discovery of TP53 as the key gene involved 
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with Li-Fraumeni syndrome, the now well-known hereditary tumor predisposition 
syndrome associated with p53 mutation (Malkin et. al., 1990). Since these discoveries, 
the TP53 protein and the pathway’s activators, regulators and effectors have been further 
investigated. 
The TP53 protein is comprised of five key domains, two adjacent trans-activation 
domains at the n-terminus, the second of which includes a proline-rich region, a DNA 
binding domain, an oligomerization domain critical for the formation of the p53 tetramer 
and a C-terminal domain that contains three nuclear localization signal elements (Figure 
5A) (Joerger and Fersht 2016). For successful transcription, TP53 must form a tetrameric 
complex, reliant on the oligomerization domain, which is capable of binding to its 
effectors at the DNA binding domain (Zauberman et. al., 1993). The transactivation 
domains influence which effectors are activated by TP53, with loss of the first 
transactivator domain leading to widespread failure to activate most target genes, 
including MDM2 but not Perp or Bax, thereby permitting tumor suppressive functions via 
apoptosis but not cell cycle arrest, whereas loss of the second domain had only minor 
effects on TP53 transcription (Jimenez et. al., 2000, Brady et. al., 2011). The C-terminal 
domain is a key component of TP53 regulation, containing the ubiquitination site targeted 
by MDM2, the chief regulator of TP53 activity (Hamard et. al., 2013). 
MDM2, as well as its family member MDM4, are the key regulators of p53 
transcription (Wang et. al., 2001, Lahav et. al., 2004). MDM2 is a RING-finger e3 
ubiquitin ligase capable of inhibiting TP53 by ubiquitinating sites in both the DNA 
binding domain and the C-terminal domain, whereas the highly similar MDM4 is able to 
bind but not ubiquitinate TP53 (Xia et. al., 2008, Barboza et. al., 2008). Ubiquitination of 
TP53 is capable of inhibiting transcription through several mechanisms, including 
directly preventing transcription, inducing nuclear export, and promoting degradation of 
cytoplasmic TP53 via the 26S proteasome (O’Keefe et. al., 2003). Failure to regulate 
TP53 function can be catastrophic, with a null mutation in MDM2 causing embryonic 
lethality in animal models and even partial inactivation leading to phenotypic 
abnormalities (Jones et. al., 1995, Pant et. al., 2016). While TP53 is generally tightly 
regulated by MDM2, in times of cell stress the p53 pathway is activated through two key 
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responsive elements, P14ARF (p19ARF in mouse), typically activated in response to cellular 
or oncogenic stress, and ATM/ATR (Figure 1), activated as a result of DNA damage, as 
might be induced through ionizing radiation (Bouvard et. al., 2000, Suh et. al., 2011). 
Both of these elements interfere with MDM2 function, with ATM/ATR inducing 
phosphorylation of TP53 both directly and through CHK1/2, and ARF binding MDM2 
and sequestering it in the nucleolus. In either case, inhibition of MDM2 function leads to 
a temporary accumulation of transcriptionally active TP53 in the nucleus. In the absence 
of MDM2 to serve as a regulator, TP53 is a potent transcription factor with effectors 
involved in a myriad array of processes, including cell cycle arrest and apoptosis, as well 
as DNA repair, senescence, autophagy, ferroptosis and metabolism (Polyak et. al., 1997, 
Tokino and Nakamura 2000, Riley et. al., 2008, Li et. al., 2012, Jiang et. al., 2015). The 
TP53-mediated cell cycle arrest response is primarily controlled by tumor suppressor 
p21CIP1/WAF1, encoded by the gene CDKN1A, a CDK inhibitor capable of inducing G1 
arrest (El-Deiry et. al., 1994, Deng et. al., 1995). The apoptotic activities of TP53 are 
engaged through multiple effectors, including NOXA and PUMA, inhibitors of anti-
apoptotic gene BCL2, and BAX, which directly activates the intrinsic apoptotic pathway 
(Nakano and Vousden 2001, Joerger and Fersht 2016). Which of these effectors activated 
is regulated through several mechanisms, including promoter binding affinity, protein 
modification, and epigenetic regulation. In general, promoter binding affinity can be 
generalized into high and low affinity binding sites , with many of the high affinity 
binding sites corresponding with cell cycle arrest targets, such as P21, and low affinity 
binding sites with apoptotic targets, such as Bax (Ludwig et. al., 1996, Szac et. al., 2001, 
Inga et. al., 2002). Further, the TP53 protein can be altered in a variety of ways that 
predispose the transcription factor activity to different binding sites, such as 
phosphorylation of Ser-46, leading to transcription of p53AIP1, and acetylation of Lys-
117, required for p53 apoptotic response (Oda et. al., 2000, Li et. al., 2012). This wide 
array of effectors also contains MDM2, thereby forming a negative feedback loop capable 
of attenuating TP53 signaling following stress.  
A variety of p53 mutant alleles have been developed in order to study p53 
function in the mouse model. Some of the more well known of these mutant alleles make 
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use of hotspot mutations, meant to imitate human disease, such as the p53R172H mutant, 
which resembles the human p53R175H hotspot (Joerger and Fersht 2016). An infrequent 
mutation to the same hotspot produces the p53R172P mutant, a hypomorph allele identified 
in only 8 human patients (Edlund et. al., 2012). However, this allele provides a useful 
experimental system, retaining partial cell cycle arrest activity, chromosomal repair 
function, and MDM2 feedback regulation while ablating the p53-mediated apoptotic 
response (Liu et. al., 2004). Using this allele as a homozygous germline mutation, mice 
develop lymphoma and sarcoma between 7-12 months of age, compared with 4-8 months 
in p53 null mice, with less evidence of DNA damage in the resultant tumors (Liu et. al., 
2004). An additional p53 allele of recent interest is the p533KR model, which replaces 
lysine to arginine at three acetylation sites, 117, 161 and 162, thereby producing a p53 
with no p53-mediated apoptosis, senescence or cell cycle arrest, but retaining metabolic 
regulation activity (Li et. al., 2012). These new p53 alleles provide the opportunity to 
study the effects of p53 transcriptional activity with greater specificity than previous 
models have allowed. 
The role of TP53 in cerebellar development has not been fully explored. Loss of 
p53 has few associated phenotypes in the murine model, although hGFAP-Cre mediated 
p53 disruption is capable of inducing MBs in approximately 10% of affected animals 
(Zhuo et. al., 2001, Wang et. al., 2009). Although no phenotypic alteration is observed in 
the cerebellum of p53 null mice, hyperactivity of p53 as induced by MDM2 loss leads to 
a drastic reduction of cerebellum (Malek et. al., 2011). The effect of MDM2 loss was 
completely rescued with the loss of p53 and partially rescued by introduction of 
homozygous p53R172P, which resulted in reduced cerebellar size and foliation (Liu et. al., 
2007).  This demonstrates that the role of p53 during cerebellar development is a highly 
potent inhibitory effect, but also shows that this role is highly regulated, affecting only 
developmental cells only rarely. 
1.6 The Hedgehog Signaling Pathway  
The Hedgehog pathway was initially discovered in Drosophila, where it plays a 
critical role in embryonic patterning (Nüsslein-Volhard and Wieschaus 1980, Hooper and 
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Scott 1989). In vertebrates, loss of Sonic hedgehog signaling led to defects in neural plate 
formation, absence of hind limbs, and cyclopia (Chiang et. al., 1996, Marigo et. al., 
1996). Vertebrate hedgehog signaling is maintained in an inactive state without ligand 
stimulation, wherein the transmembrane receptor protein Patched (PTCH1) inhibits the 
function of the G-protein coupled receptor-like protein Smoothened (SMO) (Figure 2) 
(Marigo et. al., 1996, Stone et. al., 1996, Lee et. al., 2006). The GLI family of zinc-finger 
transcription factors, consisting of GLI1, GLI2 and GLI3, are the key downstream 
effectors of hedgehog signaling (Fuccillo et. al., 2006). While Smoothened is repressed, 
trafficking of a SUFU-GLI complex at the primary cilia leads to GLI phosphorylation by 
the PKA/GSK3ß/CK1 complex prior to being processed into a transcriptional repressor 
form (Blaess et. al., 2006, Pan et. al., 2009). Binding of hedgehog ligand to PTCH1, in 
combination with co-receptors BOC, CDON, and GAS1, de-represses SMO, thereby 
allowing SMO migration to the primary cilia (Wechsler-Reya and Scott 1999, Fuccillo et. 
al., 2006, Rohatgi et. al., 2007, Corrales et. al., 2009, Izzi et. al., 2011). SMO migration 
to the primary cilia, facilitating accumulation of SUFU-GLI complex, and permits 
dissociation of SUFU and GLI, which then bypasses PKA and migrates to the nucleus as 
the active form of GLI (GliA)  (Rohatgi et. al., 2007, Briscoe and Therond 2013) This 
allows GLI-mediated transcription of numerous downstream effectors, including Ptch1, 
Gli1, Gli2, Cyclin-D and n-Myc (Oliver et. al., 2003). Through these effectors, the 
hedgehog pathway can promote both cell cycle progression and tumor initiation. 
1.7 Form, Function and Development of the Cerebellum  
The mature cerebellum is the most neuron dense tissue in the brain, accounting 
for more than 75% of the brain’s neurons (Marzban et. al., 2015). The neurons of the 
cerebellum, through a complex network of excitatory and inhibitory interactions, are able 
to translate intended movements to match with sensory and spatial inputs, calculating the 
timing of movements in coordination with other objects (Kandel et. al., 2000). Moreover, 
the cerebellum responds to the effects of these movements on the overall body, 
maintaining balance and directing the function of the sensory organs (Kandel et. al., 
2000). The coordination that the cerebellum provides arises from its role as a mediator 
circuit that regulates outgoing motor signaling, receiving sensory and motor input from 
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the brainstem, spinal cord, and inferior olive and outputting signal through the deep 
cerebellar nuclei (White and Sillitoe 2013). Much like the cerebral cortex of the 
forebrain, the cerebellum is a structurally organized tissue, comprised of a three layered 
cortex over an interior comprised of cerebellar white matter (Figure 3) (Roussel and 
Hatten 2011). The cerebellar signaling network is comprised of 5 major neuron types, the 
glutamatergic granule cells, and the GABAergic Purkinje, basket, stellate and Golgi cells, 
as well as three rare interneuron populations, the glutamatergic unipolar brush cells, and 
the GABAergic candelabrum and Lugaro cells (Kandel et. al., 2000, Schilling et. al., 
2008). Afferent signals are carried to the cerebellum by mossy fibers from the spinal cord 
and brainstem, which act as excitatory signals on cerebellar granule cells and deep 
cerebellar nuclei, and climbing fibers from the inferior olive, which directly activate 
Purkinje cells and deep cerebellar nuclei (Gilbertson and Ellison 2008). Cerebellar 
granule cells occupy the densely populated granular layer, from which their axons extend 
into the molecular layer. These axons bifurcate and extend in straight lines through the 
molecular layer, forming a dense structure comprised of granule cell axons called the 
parallel fibers, each of which activates multiple Purkinje cells (Kandel et. al., 2000). 
Between the molecular and granular layer lies the Purkinje layer, comprised primarily of 
Purkinje cells, large neurons that carry inhibitory signal to the deep cerebellar neurons, 
and Bergmann glia, cerebellar astrocytes supporting the surrounding neurons (Kandel et. 
al., 2000). Purkinje cells function as inhibitors of efferent signaling, receiving excitatory 
impulses from granule cells and climbing fibers that lead to inhibitory signal to deep 
cerebellar neurons (White and Sillitoe 2012). 
During embryonic development, the tissue of the central nervous system arises 
from the ectodermal germ layer (Figure 4A) (Kandel et. al., 2000). Initial transformation 
into neuroectodermal cells is a process regulated by interplay in bone morphogenetic 
protein (BMP) signaling pathway, with BMP4 secreted from the lateral edges of the 
ectoderm and opposed by BMP antagonists Follistatin, Chordin and Noggin, secreted by 
the notochord and dorsal mesoderm (Kandel et. al., 2000, Marzban et. al., 2015). High 
BMP stimulates epidermal transformation whereas low signal leads to neuroectodermal 
cells forming the neural plate and the intermediary region forming the neural crest, the 
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source of the peripheral nervous system. Once formed, the neural plate folds inward to 
form the neural tube, a process reliant on Hedgehog signaling from the notochord and 
floor plate (Kandel et. al., 2000, Marzban et. al., 2015). Discrete brain structures appear 
along the anterior-posterior axis of the neural tube, resulting from signaling factor 
gradients as well as a wide array of Homeobox (Hox) and Hox-like transcription factors, 
including Engrailed 1 and 2 (En1/En2), Otx2 and Gbx2, genes crucial for proper 
cerebellar formation and patterning (Wang and Zoghbi et. al., 2001). The isthmus region 
found between the mesencephalon, the midbrain, and the rhombencephalon, the 
hindbrain, controls patterning of these regions through FGF8 and Wnt1 paracrine 
signaling (Yaguchi et. al., 2009, White and Sillitoe 2012, Marzban et. al., 2015). 
Posterior to the isthmus organizer region, the neural tube forms the hindbrain, itself 
subdivided into eight rhombomeres, with rhombomeres 1-3 forming the metencephalon, 
which gives rise to the cerebellum and pons, and 4-8 forming the myelencephalon, which 
forms the medulla (Kandel et. al., 2000). 
Transformation from neural tube to cerebellar primordium begins at embryonic 
day 8 (E8) from the fourth ventricle at rhombomere 1. The cerebellar primordium 
continues to develop with the formation of the two distinct germinal zones involved in 
formation of the cells of the cerebellum, the rhombic lip and roof of the fourth ventricle 
(Kandel et. al., 2000, Gilbertson and Ellison 2008). The rhombic lip germinal zone 
produces glutamatergic neurons, including excitatory projection neurons of the deep 
nuclei from E10-E12, granule cell precursors from E12-16 and unipolar brush cells from 
E14-18. The fourth ventricle germinal zone, on the other hand, produces GABAergic 
neurons, including inhibitory deep nuclei neurons also from E10-E12, Purkinje cells from 
E10.5 to E12.5, and several other interneuron types from E14 to E18. After birth, 
projection neurons migrate to the rostral end of the cerebellar plate and form the deep 
cerebellar nuclei. Purkinje cell placement is a critical organizer for the cerebellum, highly 
regulated by transcription factors Ebf2 and Engrailed 1 and 2 (Kandel et. al., 2000, 
Gilbertson and Ellison 2008, Marzban et. al., 2015). Embryonic Purkinje cells migrate 
into clusters at E14 from which they will then form a monolayer in the postnatal 
cerebellum a process completed by postnatal day 5 in rodents, a process controlled 
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through Reelin signaling from the nascent EGL (Fatemi 2008). As this process proceeds, 
granule precursor cells, born in the rhombic lip, begin to migrate along the exterior dorsal 
surface of the cerebellar anlage, proceeding from posterior to anterior (Figure 4B). 
Covering the cerebellum by E15, the granule precursors form the external granular layer 
(EGL), the source of granular neurons (Aruga et. al., 2002, Klein et. al., 2005, Gilbertson 
and Ellison 2008). Postnatally, granular cell precursors proliferate and expand into 
several layers in response to paracrine SHH signaling from the Purkinje cells, and the 
innermost granule cell precursors begin to differentiate into granular neurons into 
granular neurons (Dahmane and Ruiz i Altaba 1999, Wechsler-Reya and Scott 1999, 
Behesti and Marino 2009). This differentiation process of the granule cell precursors is 
controlled by a combination of bFGF, BMP and Notch signaling and downstream targets 
Math1 and Zic1 (Aruga et. al., 2002, Gazit et. al., 2004, Fogarty et. al., 2007, Salero and 
Hatten 2007). As EGL cells exit the cell cycle, they begin to express p27Kip1, a cell cycle 
inhibitor, and begin to differentiate into neurons. These neurons then migrate inward, 
following fibers from Bergmann glia, until they reach the inner granule layer, where they 
differentiate and begin to extend axons into the molecular layer. Granular cell precursors 
remain proliferative until about P14, after which they will also differentiate and migrate 
into the granular layer (White and Sillitoe 2013). At this point, the only remaining 
process in cerebellar development is formation of the cerebellar neural circuitry, an 
ongoing process that is largely complete by P21, but will continue into adulthood (Reeber 
et. al., 2013). At P21, the EGL is fully depleted, with all EGL cells having differentiated 
into neurons or been eliminated.  
Hedgehog signaling plays a significant role in cerebellar development, which is 
reflected in MB initiation. Hedgehog ligands are secreted by Purkinje cells during 
postnatal cerebellar development, and functions to promote GCP proliferation (Dahmane 
and Ruiz I Altaba 1999, Fogarty et. al., 2007). Loss of SHH ligand secretion inhibits the 
ability of the cerebellum to properly develop folia (Dahmane and Ruiz I Altaba 1999, 
Wechsler-Reya and Scott 2002). On the other hand, activation of the Hedgehog signaling 
pathway through Ptch1 inactivation prevents proper differentiation of granular precursor 
cells, leading to retained EGL following P21 (Oliver et. al., 2005). This function of the 
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Hedgehog pathway is dose dependent, with the homozygous loss of Ptch1, using a 
conditional knockout specific to Math-1 positive GCPs, during development leading to a 
greater enlargement of cells of the EGL (Yang et. al., 2008). Although the key 
mechanism attributed to Hedgehog pathway dysfunction regards maintenance of 
proliferative GCP-like cells in the cerebellum, an alternate mechanism proposed is a 
result of crosstalk between the SHH and p53 signaling pathways (Abe et. al., 2008, Po et. 
al., 2010, Malek et. al., 2011). This regulation is carried through multiple routes, with n-
Myc increasing transcription of MDM2 and Gli1 indirectly causing MDM2 activation, as 
demonstrated by the decreased EGL proliferation and size observed in cerebellum 
without functional MDM2/MDM4 (Malek et. al., 2011). 
The growth advantage provided by Ptch1 homozygous inactivation is supported 
by the frequent inactivation of Ptch1 noted in the Ptch1+/- mouse model, which has been 
demonstrated to undergo loss of heterozygosity in 70-100% of the mice (Wetmore et. al., 
2000, Yang et. al., 2008, Ward et. al., 2009, Tamayo-Orrego et. al., 2016). It has been 
proposed that loss of heterozygosity, and by association Hedgehog pathway 
hyperactivation, is a required early event in the development of SHH-MBs (Tamayo-
Orrego et. al., 2016). Several Hedgehog pathway components or downstream targets 
contribute to the development of MB. Inactivation of Gli1 by deletion of the zinc finger 
domain has been shown to reduce the penetrance of MBs in the Ptch1+/- background 
drastically, from 24% in Ptch1+/- model to 3.4% in Ptch1+/-;Gli1-/- model (Weiner et. al., 
2002, Kimura et. al., 2005). Although retention of Gli1 provides a potent advantage for 
tumor development, it was found that deactivation of Gli1 was fully compensated for by 
Gli2 activity (Weiner et. al., 2002, Kimura et. al., 2005). However, activation of 
downstream target n-Myc is a crucial target of SHH signaling in giving rise to MBs 
(Zindy et. al., 2006, Hatton et. al., 2006, Thomas et. al., 2009). Demonstrated as a key 
factor in cerebellar development required for proper expansion of the EGL, n-Myc loss 
was shown to completely rescue MB penetrance in the ND2:SmoA1 mutant mouse model 
(Knoepfler et. al., 2002, Hatton et. al., 2006).  
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1.8 MB Mouse Models and Cell of Origin 
1.8.1 Murine Models of SHH-MB 
Thanks to early investigation into molecular biology of MBs through the 
association with Gorlin and Turcot syndromes, the SHH-associated MB mouse model 
was established. The earliest transgenic model of SHH-MB was the germline Ptch1+/- 
model developed in 1997 (Goodrich et. al., 1997). As a model meant to mimic Gorlin 
syndrome, several features were held in common between these animals and patients, 
including rare limb defects, especially in the digits, an increase in body tumors, and an 
increase in brain tumors, although basal cell carcinoma was not observed in this 
background, a reversal from the epidemiology associated with Gorlin syndrome in 
humans. When backcrossed into the 129SV background, the model produced MBs in 
22% of animals examined (Goodrich et. al., 1997). Mouse background was capable of 
drastically influencing penetrance in the Ptch1+/- model, with reported penetrance as low 
as 6.7% and as high as 55% noted within the literature (Wetmore et. al., 2001, Pazzaglia 
et. al., 2002, Kimura et. al., 2004, He et. al., 2014, Mille et. al. 2014, Tamayo-Orrego et. 
al., 2016). In order to improve penetrance, the Ptch1+/- model was crossed with mutant 
alleles of several potential genes of interest, including Apc, p19Arf and p53 (Wetmore et. 
al., 2001). Within these models, only p53 inactivation was capable of altering penetrance 
compared to Ptch1+/- alone, increasing the penetrance while lowering the median survival, 
reproducing the germline Li-Fraumeni syndrome within the mouse model (Wetmore et. 
al., 2001). Because of the scarcity of TP53 mutations in MBs, several alternative models 
of MB were developed making use of alterations to the Hedgehog pathway. 
Constitutively activated Smoothened, SmoW539L, induced MBs with higher penetrance in 
multiple mouse models, including ND2:SmoA1, a germline mutant driven by the 
cerebellar granule cell specific Neurod2 promoter capable of 50% MB penetrance, and 
R26SmoM2, a Cre-activated allele capable of inducing MBs with 100% penetrance with 
hGFAP-Cre (Hallahan et. al., 2004, Mao et. al., 2006, Ahlfeld et. al., 2013). Activation of 
smoothened in these models An alternate approach to produce MBs with high frequency 
is to use a Cre driver to target Ptch1 for homozygous loss, thereby overcoming 
embryonic lethality (Ellis et. al., 2003, Adolphe et. al., 2006). Introducing this 
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background with drivers targeting stem and progenitor cells of the cerebellum was 
capable of generating tumors with nearly complete penetrance (Yang et. al., 2008). 
1.8.2 Cell of Origin for SHH-MB 
Initial studies using the Ptch1+/- model were able to demonstrate a population of 
abnormally retained cells in the postnatal cerebellum occupying the developmental 
external granular layer (Kim et. al., 2003, Oliver et. al., 2005). These cells, although 
retaining markers associated with the normally differentiated population of cerebellar 
GCPS, remained proliferative and were associated with the location in which MBs 
developed. By using Math1-GFP in the Ptch1+/- model to track cells that give rise to 
MBs, it was demonstrated that the GCP lineage is a source for SHH-MBs (Oliver et. al., 
2005). Math1 is required for Gli2 expression during cerebellar development, and loss of 
Math1 reduced proliferation of GCPs (Flora et. al., 2009).. Using the GCP marker Math1 
for conditional deletion of Ptch1 in the the Math1-Cre;Ptch1flox/flox model, thereby 
increasing tumor penetrance and median survival as effectively as is seen in the Ptch1+/-
;p53-/- model (Yang et. al., 2008). Curiously, Nestin-expressing cells are found amongst 
the GCPs of the postnatal EGL, and Nestin-expressing cells represent only a rare 
subpopulation in the postnatal EGL, use of either Math1-CreER or Nestin-CreER in a 
Ptch1floxflo/x model were capable of inducing MBs (Li et. al., 2013). A survey of the 
capacity of various cerebellar cells capability to give rise to SHH-MBs made use of a 
panel of Cre drivers, including Math1, Tlx3, hGFAP, Olig2 and Gli-CreER, to 
demonstrate that SHH-MB may arise from various stages of EGL development (Schuller 
et. al., 2008).  
One of the characteristic features discovered in the mouse MB model is the 
presence of abnormally retained pre-neoplastic cells sharing the location and believed to 
be derived from the external granular layer. In the Ptch1+/- model, retained cells were 
observed in mature cerebellum following the complete migration of the GCP population 
(Oliver et. al., 2005, Matsuo et. al., 2013). Curiously, the frequency of these lesions was 
noted to decrease following postnatal day 21, from 84% of animals showing enrichment 
at 6 weeks to 16% at 10-25 weeks (Oliver et. al., 2005). Cells within MBs also express 
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stem and progenitor markers, leading to some suggestion that MBs may harbor a stem-
like population. Several cerebellar precursor markers, including Nestin and Sox2, have 
been found in mouse xenograft MBs established from an GFAP-Cre;Rbx/x;p53-/- model 
(Marino et. al., 2000, Sutter et. al., 2010). By investigating the relation between 
molecular subgroups and Sox2 expression, it was found that frequent Sox2 labeling 
corresponds with the SHH-MB signature, as well as cells of the embryonic rhombic lip 
germinal zone (Ahlfeld et. al., 2013). Although conditional knockout of Sox2 had no 
impact on MB penetrance in the SmoM2 model, it was shown that loss of Sox2 in 
cultured GCPs was capable of decreasing the proliferative population (Ahlfeld et. al., 
2013). Characterization of the Sox2-positive cell population found in SHH-MBs revealed 
that these rare cells were frequently quiescent and molecularly similar to neural stem and 
granule cell precursors, but apparently were responsible for producing a transient 
amplifying population of MB cells (Vanner et. al., 2014). Moreover, following 
chemotherapeutic treatment with either vismodegib, the Smo inhibitor, or Ara-c, an 
antimitotic agent, it was found that Sox2-positive cells were enriched, demonstrating that 
these cells have greater treatment resistance compared to the tumor mass. Although it is 
not certain, some studies have proposed that the presence of stem cell markers in a 
quiescent cell population indicate the existence of a MB cancer stem cell (Fan and 
Eberhart 2008, Hambardzumyan et. al., 2008, Vanner et. al., 2014). However, although it 
seems clear that MB cells may have qualities attributed to stem cells, this direction has 
not been thoroughly investigated and has not yet been successfully leveraged into 
developing a therapeutic approach.  
1.8.3 MB Models for other Subtypes 
Producing mouse models for other models of MBs was a challenging endeavor 
that initially met with few positive results. The Wnt subtype MB model was unable to 
provide a model capable of producing tumors, partially due to a misunderstanding of the 
underlying biology of the Wnt subtype (Lorenz et. al., 2011).  While the cell of origin for 
the SHH-MB subtype was demonstrated as precursor cells of the rhombic lip and EGL, a 
different cerebellar population, the cells of the lower rhombic lip and embryonic dorsal 
brainstem are associated with Wnt subtype MB based on gene expression patterns 
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(Gibson et. al., 2010). This corresponds with the location of these tumors in human 
patients, where the Wnt subtype often occupies the fourth ventricle and invades the brain 
stem. Two models for the Group 3 MB subtype were developed in 2012, using either 
transfection of GCPs from an CDKN2C/p53 null background with c-Myc expressing 
retrovirus or transfection of both nonfunctional p53 and active c-Myc (Kawauchi et. al., 
2012, Pei et. al., 2012). Unlike human disease, where p53 mutation is not associated with 
the Group 3 MB subtype, addition of p53 is required for either of these models to develop 
tumor. An additional study, making use of GFI1 and GFI1b, was able to induce an 
oncogenic transformation in neural stem cells by infecting them with GFI1 or GFI1b in 
conjunction with c-Myc, and thereby produce tumors that match Group 3 tumors by 
molecular characterization (Northcott et. al., 2014). 
1.8.4 p53 Mutant MB Models 
Incorporation of mutant p53 within the Ptch1+/- model increased SHH-MB 
penetrance to 100%, providing clear correlation between p53 activity and suppression of 
MB (Wetmore et. al., 2001). Although murine MB models were typically developed 
using genes corresponding to at least one of the specifically mutant subtypes, several 
models were capable of inducing MBs by targeting tumor suppressor pathways alone. A 
model featuring deletion of both p53 and Rb following GFAP-Cre mediated 
recombination gave rise to aggressive tumors resembling LCA morphology and 
expressing high levels of Gli2 and n-Myc (Shakhova et. al., 2006). Making use of the 
TUNEL assay, it was found that apoptosis was very rarely observed, but that loss of Rb 
was capable of inducing both increased proliferation and apoptosis in cells of the EGL 
and IGL (Shakhova et. al., 2006). Inactivation of both Rb and p53 was capable of further 
driving apoptosis in the IGL, but failed to promote additional apoptosis in the developing 
EGL, indicating that p53 is a key component of a suppressive response within the 
developing cerebellum, though not of all cells (Shakhova et. al., 2006). Moreover, 
although loss of p53 at the germline did not give rise to MBs, conditional loss of p53 
alone was capable of inducing MB formation, as was seen with the p53∆E5-6 model, which 
was capable of inducing MBs, though only in approximately 10% of animals, with the 
remainder developing glioblastomas (Wang et. al., 2009). The successful induction of 
24 
MBs within the p53∆E5-6 model provides a potentially advantageous direction compared to 
previous p53 conditional knockout models, as the recombined p53 will form a non-
functional protein following pathway activation that will accumulate in stressed cells 
without inducing transcription. In this way, accumulation of p53 may be used as a marker 
for stressed cells (Lin et. al., 2004, Wang et. al., 2009).  
1.8.5 Irradiation of Granule Cell Precursors and MB 
The genetic damage caused by radiation therapy can increase the risk of a patient 
developing a second cancer after treatment. The incidence of second cancers is increased 
in both Li-Fraumeni and Gorlin syndrome patients, indicating that inactivation of the p53 
or Hedgehog pathways sensitize cells to genetic damage (Hisada et. al., 1998, Pazzaglia 
et. al., 2002). Within the Ptch1+/- mouse model, irradiation of GCPs increased the 
frequency of MB formation, although the timing of radiation treatment proved to be a 
determining factor in this approach’s efficacy (Pazzaglia et. al., 2006). Treatment with 
irradiation at postnatal day 0.5 (P0.5) is capable of inducing MBs in 81% of specimens, 
compared with only 7% of specimens if untreated or 3% if treated at postnatal day 10 
(P10). At a molecular level, this behavior was attributed to a differential radiation 
response between the cells of the P0.5 and P10 EGL, with neither p53 or apoptosis 
detected in irradiated P0.5 EGL, while the P10 EGL activated a robust p53 response 
(Pazzaglia et. al., 2006). This reduced radiation response was also observed in the 
embryonic rhombic lip, though not in the 4th ventricle germinal zone (Tanori et. al., 
2013). Likewise, MB cells located in the perivascular niche are associated with cell 
survival following radiation in the Ptch1+/- model (Hambardzumyan et. al., 2008). This 
response was also reliant on p53 activation, with p53 only activating outside of the 
perivascular niche and corresponding to cell survival in these regions.  
1.9 Summary and Significance 
In summary, MBs arise from stem and progenitor populations of the developing 
cerebellum, where elevation of the Hedgehog pathway drives tumor formation. Unlike 
most tumors, MBs rarely inactivate the p53 pathway, retaining wild type p53. One of the 
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relevant directions in MB research is determining how MBs are capable of forming 
without inactivating the p53 pathway. I propose that the cell of origin of SHH-MBs may 
be unable to elevate p53 to a level capable of removing these cells through normal 
developmental processes, thereby permitting tumor progression even in the presence of 
wild type p53. In order to address this question, I developed mouse models with reduced 
potential p53 response, making use of p53∆E5-6 and p53R172P, and then increased p53 
response in these models by inducing radiation stress (Liu et. al., 2004, Wang et. al., 
2009). In Chapter 2, I will present research related to the initiation and progression of 
MBs and the role p53 plays in this process, making use of the three tiers of p53 response 
to demonstrate that discrete functions of p53 play separate roles throughout development.  
In Chapter 3, I will discuss the effects of elevating p53 activity through the use of 
radiation therapy, either in PNLs or MBs. The final chapters present the techniques used 
and a discussion of the implications of the data shown in this study.   
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Figure 1: The p53 Signaling Pathway 
Cells maintain tumor suppressor TP53/p53 in an inactive state through basal expression 
of MDM2. When MDM2 binds to p53, it regulates p53 transcription activity through 
several mechanisms, including facilitating nuclear export and ubiquitination that 
suppresses chromosome interaction and promotes degradation of cytoplasmic p53. 
Following either oncogenic stress or chromosome damage, upstream targets ARF or 
ATM/ATR will be activated, respectively. Activation of these proteins enables p53 
transcription by either protecting p53 through phosphorylation in the case of ATM/ATR, 
or through targeting MDM2 in the case of ARF. Once MDM2 repression is alleviated, 
p53 transcription factor activity is restored. Wild type p53 maintains a range of targets, 
including negative receptor MDM2, apoptotic targets Bax and Noxa, and cell cycle arrest 
target p21. Different p53 targets are controlled by promoters with varying p53-affinity 
thereby allowing differential response to p53 activation. High affinity promoters are 
typically associated with cell cycle arrest targets, like p21, whereas low affinity targets 
tend to correspond with apoptotic genes. The p53R172P protein is a p53 hypomorph with 
decreased functionality, which fails to activate low-affinity binding while retaining high-
affinity promoter binding (Liu et. al., 2004). The p53∆E5-6 allele expresses a conditional 
knockout that, following Cre-mediated recombination, loses a large portion of the DNA 
binding domain, and therefore loses transcription activity (Wang et. al., 2009).  
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Figure 2: The Sonic Hedgehog Pathway 
The hedgehog pathway, without ligand activity, remains in a repressed state as trans-
membrane protein Patched (Ptch1) inhibits the activity of Smoothened (Smo). Without 
Smo, the GLI2 and GLI3 transcription factors form a complex with SUFU, which is 
moved to the primary cilia at low levels and are targeted by the PKA/GSK/CK1 complex 
for phosphorylation while leaving the primary cilia. Phosphorylated GLI2/3 are subject to 
proteolytic conversion into the GLI repressor form, which migrates to the nucleus and 
inhibits SHH signaling. Following SHH ligand binding to Ptch1, Smo migrates to the 
primary cilia where it facilitates accumulation of GLI-SUFU complex. Active HH 
pathway then permits dissociation of SUFU and GLI, which then bypasses PKA and 
migrates to the nucleus as the active form of GLI (GliA), activating downstream 
transcription targets, including Ptch1, Gli1 and n-Myc. 
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Figure 3: Cerebellar Organization 
The cerebellum is comprised of a three-layered cortex overlying a white matter core. 
Mossy and climbing fibers carry signal to the cerebellar neurons, where, through a 
complex interaction between the glutamatergic and GABAergic interneurons of the 
cerebellum, an efferent signal is carried by the cerebellar deep nuclei. The initial neurons 
targeted by the mossy fibers are granular neurons, the most common neuron of the 
cerebellum, located in the granular layer, which matches with the developmental inner 
granular layer. Each granular cell extends a lengthy axonal process into the molecular 
layer, forming a compact network of axonal processes called the parallel fibers. These 
fibers carry signal to the dendrites of Purkinje cells, occupying the aptly named Purkinje 
layer, in turn directly inhibiting outgoing signal at the deep nuclei.  Several varieties of 
GABAergic interneurons, including the Golgi cells of the granular layer, which target 
Granular Neurons, and Mossy and Basket cells of the molecular layer, inhibiting Purkinje 
cells. Bergamann Glia, located in the Purkinje layer, are crucial support cells for the 
processes of the molecular layer, and also involved in neuronal migration during 
development.   
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Figure 4: Cerebellar Development and MB initiation 
(A) During embryonic cerebellar development, two germinal zones arise in the 
cerebellum, the rhombic lip and the 4th ventricular zone. The rhombic lip gives rise to 
glutamatergic cells, including deep cerebellar neurons, the excitatory efferent signaling 
apparatus of the cerebellum, arising from the upper rhombic lip and granule cell 
precursors from the lower rhombic lip. The 4th ventricle germinal zone gives rise to 
GABAergic neurons, including inhibitory deep cerebellar neurons, Purkinje cells and 
most cerebellar interneurons. During embryonic development, the rhombic lip births the 
cells of the deep nuclei and a population of Granule Cell Precursors, which form a thin 
layer occupying the exterior surface of the cerebellum. Meanwhile, Purkinje cells migrate 
from the 4th ventricle into clusters, which will expand into the Purkinje layer postnatally 
in response to Reelin signaling as well as other factors. 
(B) Postnatally, the Granule cell precursors expand in response to SHH secreted by the 
Purkinje cells.  Proliferative Granular Cell Precursors form the outer external granular 
layer. As the layer expands, cells begin to differentiate into a neuronal population, 
forming the inner external granular layer, in response to FGF and BMP signaling. These 
differentiating granule cells migrate along processes extending from the Bergmann glia 
toward the internal granular layer, where they will fully differentiate. In general, granule 
cell precursors stop proliferating around postnatal day 15 in mice, and the external 
granular layer is completely absent by postnatal day 21. In mice with abnormal Hedgehog 
pathway activity, a population of GCP-like cells remains in the EGL even after P21, and 
are thought to represent the cell of origin for SHH-MBs. 
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Chapter II: p53-mediated Apoptosis Targets Granule 
Cell Precursors during Cerebellar Developmental 
thereby Suppressing medulloblastoma 
2.1 Introduction 
TP53 tumor suppressor gene is the most frequently mutated gene in human 
cancer, with 50% of tumors featuring a mutation in the TP53 allele and many other 
tumors showing p53 pathway inactivation. Medulloblastoma (MB) is an exception to this 
tendency, with only 10% of tumors demonstrating loss of p53 function (Louis et. al., 
2007). The presence of mutant p53 is of prognostic significance in only one of the MB 
subgroups, the Sonic Hedgehog (SHH) pathway associated MBs (Zhukova et. al., 2013). 
Further, MBs arising in Li-Fraumeni patients, harboring germline loss-of-function 
mutations in the TP53 tumor suppressor gene, have been molecularly characterized as the 
SHH-MB subgroup (Kool et. al., 2014). However, p53 mutations are increased following 
standard therapy, indicating that p53 activation is crucial for the treatment response of 
SHH-MBs (Morrissy et. al., 2016).  The role that p53 plays during cerebellar 
development and how this contributes to MB formation is not well understood.  
The cell of origin for SHH-MBs has been established as part of the GCP lineage, 
proliferative cells located in the postnatal EGL, as demonstrated by the formation of 
SHH-MBs after targeting either Math1+ or hGFAP+ cells of the ventricular zone located 
on the lower rhombic lip (Schuller et. al., 2008, Yang et. al., 2008, White and Sillitoe 
2013). Loss of heterozygosity in the Ptch1 heterozygous mice (Ptch1+/-) triggers the 
generation of Ptch1-/- pre-neoplastic lesions (PNLs) in the developing EGL, a small 
number of which can eventually progress and form MBs (Tamayo-Orrego et. al., 2016). 
The tumor suppressive mechanism that eliminates the majority of Ptch1-deficient PNLs 
remains unknown, but the cells of the EGL are sensitive to p53 hyper-activation 
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following MDM2/MDM4 disruption (Malek et. al., 2011). This leads to my hypothesis 
that the p53 response is activated in rare cells of the postnatal cerebellum to eliminate 
granule cell precursors (GCPs) undergoing oncogenic stress. 
In this chapter, I have employed a combination of mutant p53 alleles within the 
Ptch1-deficient MB model, Ptch1p53WT (Ptch1+/-;p53∆E5-6/∆E5-6). The Zhu lab has 
developed a combination of mouse models, making use of a Cre-mediated p53 exon 5 
and 6 in-frame deletion, targeting the p53 DNA binding domain and preventing p53 
transcription following recombination, to produce the Ptch1p53∆E5-6 model (hGFAP-
Cre;Ptch1+/-;p53∆E5-6/∆E5-6). I also developed the germline p53R172P mutant, a hypomorph 
p53 that retains partial cell cycle arrest activity while completely losing p53-mediated 
apoptotic activity (Ptch1p53∆/R172P: hGFAP-Cre;Ptch1+/-;p53R172P/∆E5-6) (Liu et. al., 2004, 
Wang et. al., 2009). These results show that activation of p53 occurs throughout Ptch1-
deficient MB development, revealing the potentially earliest MB precursor cells in the 
inner layer of the developing EGL. While p53-mediated apoptosis is the crucial p53-
mediated response to eliminate PNLs in the Ptch1 model, p53-mediated cell cycle arrest 
only delays MB progression without impacting penetrance. By making use of p53∆E5-6 as 
a marker within the PNLs, I found that two varieties of PNL were formed from GCPs and 
that these may represent two models of MB. 
2.2 Results 
2.2.1 Tumor suppressor p53 marks normal and neoplastic cells under 
oncogenic stress 
Previous effort by the Zhu lab made use of the hGFAP-Cre;p53∆E5-6/∆E5-6 model to 
induce the formation of glioblastomas and MBs, and found that p53 accumulation was 
detected by immunohistochemistry within these tumors (Wang et. al., 2009). To 
demonstrate whether p53 accumulation could serve as a marker for abnormal cells in 
addition to tumor cells, lab member Yinghua Li conducted a series of experiments 
showing the molecular activity of p53∆E5-6. In order to demonstrate that the mutant protein 
was retained in spite of the loss of two exons of the functional DNA binding domain 
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(Figure 5A), I performed a western blot using the p53 antibody, demonstrating that 
p53ΔE5-6 was detected with fidelity equivalent to wild type p53, and that blocking p53 
translation by two independent p53-specific siRNAs, but not the mismatched p53 siRNA, 
lead to a complete loss of p53 detection (Figure 5B). Further, I demonstrated that in both 
murine (Figure 5C) and human (Figure 5D-F) cell lines, activation of MDM2 was 
capable of targeting TP53ΔE5-6/p53ΔE5-6 for degradation in the same manner as is observed 
with wild type TP53/p53. These data demonstrate that mutant p53ΔE5-6 is both produced 
and regulated in the same way as wild type p53, but, in losing the DNA binding domain 
and thus p53 transcription, no longer up-regulates the MDM2/Mdm2 negative feedback 
loop. Therefore, in addition to marking tumor populations, accumulation of mutant 
p53ΔE5-6 is a marker for normal and neoplastic cell populations under oncogenic stress. 
2.2.2 Tumor suppressor p53 is activated during cerebellar development 
In order to investigate p53 activation during cerebellar development, I isolated 
control and mutant brains at postnatal day 8 (P8) from each of my mouse models, 
ascertaining that all mice were maintained on a mixed background and utilizing 
littermates to control for variation due to background (Figure 6A). I found that the p53 
protein was not stabilized in the EGL of control models, including both p53WT (p53E5-6/E5-
6) (n = 6) and Ptch1p53WT (Ptch1+/-;p53E5-6/E5-6) (n = 5), but was fully capable of 
accumulating in a subset of cells in the p53∆E5-6 (hGFAP-Cre;p53E5-6/E5-6) (n = 5) mutant. 
In Ptch1p53∆E5-6 (Ptch1+/-;hGFAP-Cre;p53E5-6/E5-6) (n = 9), PNLs, indicated by clustered 
p53-positive cells, were readily detectable in the EGL of 56% of the samples observed 
(Figure 6B). This phenomenon was largely rescued when p53-mediated cell cycle arrest 
activity was restored in the Ptch1p53∆/R172P (Ptch1+/-;hGFAP-Cre;p53E5-6/R172P) (n = 4) 
model, leading to a reduction in p53 positive cells, specifically in the EGL, as well as an 
absence of discernable PNLs (Figure 6C). Curiously, p53-positive cells were located 
within the other cerebellar layers, including the molecular layer (ML) and internal 
granular layer (IGL), where the same pattern of p53 activity was observed within all 
mutant p53 models, regardless of Ptch1 status or the mutant p53 allele (Figure 6D). Of 
note, the frequency of p53-positive cells was not statistically different between the 
Ptch1p53∆E5-6 and Ptch1p53∆E5-6 models for any cerebellar layer, demonstrating that the 
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presence of a mutant allele of Ptch1 was not sufficient to lead to p53 activation within the 
developing CB. Surprisingly, the cells of the Ptch1p53∆/R172P model, while not rescuing 
from p53 expression within the IGL or ML, were able to produce a significant reduction 
in p53 positive cells within the EGL.  These data demonstrate that the p53 response is 
temporarily activated in a rare population of cells during development, a process only 
detectable with the mutant p53∆E5-6, and that even partial function of p53 is sufficient to 
remove the majority of these stressed cells. 
2.2.3 p53 inactivation permits accumulation of abnormal cells with stem cell 
markers 
Clusters of p53 positive cells within the p53 mutant cerebella are an abnormal cell 
population, which might represent an early pre-neoplastic population. I next tried to 
characterize the behavior of these cells, in an effort to determine whether they 
represented a pre-neoplastic population, a task made difficult by the widespread 
proliferation of the GCP population, affecting 80-90% of the cells of the outer EGL at 
this developmental time-point (Figure 7A-7B). Proliferation within these p53 positive 
clusters was comparable to the outer EGL, with approximately 90% of the cells of the 
clusters in the cell cycle, unlike p53 labeled cells located within the EGL but outside of 
the clusters, where only 50-60% are proliferative (Figure 7C). These data demonstrate 
that the p53ΔE5-6 marker labels stressed GCPs, and that the cells of the p53 positive 
clusters are an abnormal, pre-neoplastic population overriding the p53 response. As 
would be predicted from the theory that the cluster is a PNL, p53 positive cell clusters 
were associated with reduced thickness of the iEGL and depleted the population of 
differentiating cells that would be seen in this layer, demonstrating these cells are able to 
already overcome developmental processes (Figure 7D). Previous studies have found that 
Sox2, an early marker of stem cells in the cerebellum normally not found after P5 is 
sustained within the Ptch1+/- model EGL (Ahlfeld et. al., 2013).  Whereas both control 
and mutant P8 EGL was found to contain few or no Sox2-positive cells, I found that the 
majority of P8 p53-positive clusters found in the p53∆E5-6 model contained widespread 
proliferative Sox2-positive cells (60%), with the remaining clusters only containing 
infrequent Sox2-positive cells (Figure 8A-B). Only Sox2 was widely expressed in these 
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clusters, with none of the clusters expressing brain lipid-binding protein (BLBP), a 
marker for the Sox2-positive Bergmann glial cells, and only one p53 positive cluster 
featuring any Nestin expression, a marker of committed granule neuron precursors in the 
CB that have been indicated as one of the cells of origin for SHH-MBs (Figure 8C-D) (Li 
et. al., 2013). Sox2 expression has been associated with hyperactive SHH signaling, 
which suggests that loss of the wild type Ptch1 allele likely occurs and triggers de-
differentiation of Ptch1-deficient GCPs to stem-like cells, initiating MB formation 
(Ahlfeld et. al., 2013). These results demonstrate that, similar to malignant glioma (Wang 
et al., 2009), the p53ΔE5-6 marker detects the earliest identified MB precursor cells in an 
otherwise morphologically normal EGL and cerebellum in the Ptch1+/- MB model. 
Further, the restoration of even partial p53 activity, as is the case with the Ptch1p53∆/R172P 
model, was sufficient to rescue the observed phenotype, suggesting that the developing 
brain is highly sensitive to p53 activation. 
2.2.4 Loss of p53-mediated apoptosis is sufficient to promote PNLs 
The widespread proliferation of the developing cerebellum has the potential to 
mask pre-neoplastic cells within the proliferative granule precursor cells present in the 
developing EGL. In order to observe the effects of partial p53 activity on formation of 
PNLs, I next investigated the accumulation of PNLs following the process of postnatal 
cerebellar development, at postnatal day 21 (Figure 9A). It has been demonstrated 
previously that within the Ptch1+/- murine MB model, the EGL fails to fully differentiate 
and PNLs remain where the EGL was located (Pazzaglia et. al., 2006, Yang et. al., 2008). 
To further investigate the function of p53 in regulating the developing EGL, mutant 
brains were collected at P22, and exhibit retained PNLs (Figure 9A).  PNL size (Figure 
9A’) and lesion frequency (Figure 9A’’) were increased in the Ptch1p53∆E5-6 model (n = 
8) compared to Ptch1p53WT control (n = 10), although the Ptch1p53WT model, on rare 
occasion, contained larger lesions of size and proliferative frequency comparable to the 
lesions seen in the Ptch1p53 mutant models. In spite of the lack of observed p53-positive 
lesions at P8, the frequency and area of PNLs in the Ptch1p53∆/R172P model (n = 9) was 
comparable to that observed in the Ptch1p53∆E5-6 model, indicating that the absence of a 
functional p53-mediated apoptotic response is the key factor for PNL penetrance. I next 
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investigated the behavior of the cells of these PNLs, focusing on apoptosis and cell cycle. 
The frequency of apoptotic cells, as represented by cleaved Caspase-3 (C-Casp3), varied 
within PNLs based on the presence of mutant p53, with 4% of cells in the Ptch1p53WT 
PNL expressing cleaved Caspase-3, but less than 2% in the samples from both p53 
mutant models, thereby demonstrating that p53-mediated apoptosis is playing a role in 
the suppression of PNLs remaining after cerebellar maturation (Figure 9B-B’). The 
similarity between the Ptch1p53∆E5-6 and the Ptch1p53∆/R172P models was further 
demonstrated by the proliferative frequency of the cells of PNLs from both the p53 
mutant models, where, in spite of the partial cell cycle arrest activity that the 
Ptch1p53∆/R172P mutant retains, no difference in proliferative frequency was demonstrated 
(Figure 9C-C’’). Curiously, both p53 wild type and mutant PNLs contained a rare 
subpopulation of Sox2-positive cells at P22, indicating that Sox2-positive cell retention is 
independent of p53. Unlike the Sox2-positive cells located within p53 positive clusters 
identified at P8, co-localization of Sox2 with either p53 or Ki67 was infrequent in PNLs 
at P22 (Figure 9D). Overall, my results from the P22 cerebellum demonstrate that 
activation of wild type p53, but not activation of the p53R172P hypomorph, eliminates most 
PNLs driven by Ptch1 loss, clear evidence that p53-mediated apoptosis is critical for 
eliminating retained GCPs following maturation of the cerebellum. 
2.2.5 Retention of p53-mediated cell cycle arrest delayed MB formation and 
prolonged survival 
Having established a clear mechanism for p53 regulation of PNL, I began to 
investigate what consequence p53 activity has on the progression of PNL into MB. Age-
matched samples collected at postnatal day 46 (P46), were collected for Ptch1p53∆E5-6, 
Ptch1p53∆/R172P and Ptch1p53WT (n = 8, 7, and 8, respectively) (Figure 10A-B’). The 
cerebellum of the Ptch1p53∆E5-6 model was visibly enlarged at this early time-point, with 
the average scale of PNLs in the model 10 fold larger than those observed in the 
Ptch1p53∆/R172P model, although mice collected at this age did not demonstrate behavioral 
symptoms (Figure 10B-B’).  This increase in cerebellar size corresponded to the 
development of early MBs in the Ptch1p53∆E5-6 model, which stands in stark contrast to 
the Ptch1p53∆/R172P model, which showed limited expansion of the PNL, and to 
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Ptch1p53WT model which showed reduced penetrance and severity of PNLs in the 
Ptch1p53WT lesion were reduced when compared to the PNLs observed immediately 
following cerebellar development (Figure 10C). These results suggest that p53 response, 
including both apoptotic and cell cycle arrest components, remain active in the GCP cells 
of the cerebellum, targeting PNLs driven by Ptch1 loss for removal, as indicated by the 
reduced penetrance observed in the Ptch1p53WT model. However, while p53-mediated 
cell cycle arrest reduces the rate of MB progression in the Ptch1p53∆/R172P model, it is 
insufficient to eliminate PNLs and instead merely curtails their growth. 
In order to better understand the effect loss of p53 function has on cellular 
behavior of PNLs, I investigated the proliferation and differentiation rate, using Ki67 and 
P27 (Figure 10D). I found that within the Ptch1p53∆E5-6 model, the frequency of 
proliferative cells was increased to approximately 58% at P46, a substantial increase 
compared to the observed frequency at P22 of 44% (p = 0.019) (Figure 10D’). Partial p53 
function, as is present in the Ptch1p53∆/R172P model, was sufficient to prevent 
accumulation of proliferative cells, and the frequency of proliferation remained similar 
from P22, at 45%, to P45, at 42% (p = 0.116). On the other hand, full p53 function, in 
addition to leading to a lower penetrance of proliferative PNLs, dropping from 60% of 
P22 samples to 37.5% at P45, also demonstrated a reduction in proliferative frequency, 
from 20% at P22 down to 5% at P45 (p = 0.046). With regards to non-proliferative cells 
of the PNL, the majority of these cells, in all three models, were marked by p27, a protein 
associated with cerebellar granule neuron differentiation during CB development (Zindy 
et. al., 2006; Miyazawa et. al., 2000). Inversely reflecting the change in Ki67, the 
frequency of P27 positive cells showed that as p53 functionality was lost, P27 frequency 
decreased, demonstrating that cell cycle arrest and differentiation were mechanistically 
linked to p53, although p53 was not the sole requirement for this process, as 
demonstrated by the fairly high (50%) frequency of p27 positivity within the Ptch1p53∆E5-
6 model (Figure 10D’’). Curiously, cells positive for both p27 and Ki67 were found 
within both the Ptch1p53∆E5-6 and Ptch1p53∆/R172P models, indicating that without fully 
functional p53 regulation, it is possible for cells in the PNL to remain proliferative in 
spite of the differentiation process. These results demonstrate that the p53-mediated cell 
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cycle arrest response targets proliferating cells of both the Ptch1p53∆/R172P and Ptch1p53WT 
PNLs, pushing pre-neoplastic cells into cerebellar granular neuron differentiation. 
2.2.6 Identification of a variant of PNLs that do not activate p53 
Having identified the roles that p53 played during cerebellar development, the 
mechanism by which PNLs were able to evade the p53 response remained unclear. 
Surprisingly, I found that, by making use of p53∆E5-6 as a marker, a variant of PNL could 
be identified in postnatal P22 cerebellum from both Ptch1p53∆E5-6 and Ptch1p53∆ /R172P 
models where no accumulation of p53 was observed, in spite of the lack of potential p53 
transcription (Figure 11A-C). These clusters, much like the clusters observed in the 
Ptch1p53WT model, showed less than 10% of the cells as p53 positive (Figure 11C). 
Curiously, it was evident that the p53R172P allele remained functional, accounting for a 
reduction in the number of clusters with high frequency of p53 positive cells (Figure 
11B). Based on the mean number of PNLs observed between models (Figure 9A’’), it 
seems likely that the increased number of PNLs observed in the Ptch1p53∆E5-6 and 
Ptch1p53∆ /R172P models compared to Ptch1p53WT is explained by the increased number of 
PNLs with stabilized p53. Thus, each of the cerebella observed contained, on average, a 
similar number of p53 negative PNLs at P22. This theory is supported by the observation 
at P46, where it was demonstrated that, within both mutant brains, there was a decline in 
the frequency of p53 negative clusters relative to the frequency observed at P22 (Figure 
11D-F). This again corresponds with the decline in penetrance of PNLs in the 
Ptch1p53WT model (Figure 10C). Thus, I show two variants of PNLs, one of which is a 
p53 negative cluster found in all of the Ptch1+/- models, and the other as a p53 positive 
cluster only observed in the context of mutant p53. These observations are most 
consistent with a model in which a subset of PNLs arise from a p53 resistant GCPs 
population, with all other PNLs requiring mutant p53 to form. 
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2.2.7 Loss of p53-mediated apoptotic activity is the crucial barrier to MB 
formation 
Following the investigation of developing tumors, I then sought to investigate the 
repercussions of p53 function on MB formation. It has been well established that loss of a 
single allele of Ptch1+/- is sufficient to induce MBs, although with less than complete 
penetrance, varying in the literature between 8% and 55%, principally varying by 
background, but increasing to nearly 100% with the inclusion of mutant p53 (Wetmore 
et. al., 2001, Mille et. al., 2014). I found the Ptch1p53WT model had median survival of 
159 days and 34% penetrance, within the range of previously reported Ptch1+/- models 
(Figure 12A-C). No significant change in penetrance or survival was observed when one 
allele of p53 was replaced with either a germline knockout p53, p53KO (Jacks et. al., 
1994), or the p53R172P allele, indicating minimal carrier effect associated with mouse 
background (Figure 12D). Homozygous loss of p53 in the Ptch1p53∆E5-6 model reduced 
median survival to 64 days and increased SHH-MB penetrance to 98%. Within the 
Ptch1p53∆/R172P model, I found a 39% increase in life span as compared to Ptch1p53∆E5-6, 
with a mean survival of 89 days and a penetrance of 95% (Figure 12A). Due to the 
presence of germline p53R172P allele, the incidence of body tumors was elevated, although 
these mice were most often sacrificed as a result of neurological symptoms (95%)  
(Figure 12B). Although these MBs arise at different rates, the MBs that arise within each 
model are not histologically or molecularly distinct. Upon dissection, I found that each 
MB model produced tumors in the same locations, most typically occupying the fourth 
ventricle (Figure 12C). Further, the tumors from each model featured similar histological 
characteristics, including nuclear molding and mitotic figures (Figure 12E). I 
characterized both proliferation and apoptosis within these MBs, and found that 
widespread proliferation was consistent through each model, with all three models 
showing mean proliferation greater than 80%, though proliferation was heterogeneous, 
with some regions showing a lower rate, and apoptosis was uncommon in all three 
models (Figure 12F-F’’). I characterized the resultant MB in order to determine whether 
tumors arising from the Ptch1p53WT model formed with any distinctive molecular 
characteristics compared to the rapid onset tumors found in the Ptch1p53∆E5-6 model, but 
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found that within all three models, the tumors had comparable labeling with 
Synaptophysin, GFAP, Nestin, and Olig2, markers used to label neural, glial, progenitor 
and oligodendrocyte populations, respectively, for pathological assessment of human 
brain tumors (Figure 12G).  
Several publications have indicated that Ptch1 loss of heterozygosity (LOH) is an 
early step in the formation of MBs within the Ptch1 background (Read et. al., 2009, 
Tamayo-Orrego et. al., 2016). To investigate whether Hedgehog pathway activity might 
play a role in differential penetrance, I investigated the frequency of Ptch1 LOH in SHH-
MBs, and found that it did not vary between models, with the majority of samples 
showing Ptch1 LOH, but with approximately 10% of samples from each model retaining 
one allele of Ptch1 (Figure 13A-B).  Expression of downstream targets of the hedgehog 
pathway, including Gli1, Gli2 and N-Myc, were increased in every tumor model, 
regardless of the status of Ptch1 LOH (Figure 13C). Curiously, expression of Gli1, Gli2 
and N-Myc was elevated in all samples, regardless of the status of Ptch1 LOH, indicating 
that the Hedgehog pathway is targeted at alternate locations. PGM sequencing using 4 of 
the non-LOH samples failed to find clonal mutations to the Ptch1 allele, demonstrating 
that the pathway was not targeted at Ptch1. Based on the elevated expression of SHH 
targets in all MBs tested, I demonstrated that, whether through LOH or an alternate 
mechanism, elevated activation of the Hedgehog pathway is a common trait of the SHH-
MB group. 
Previous studies have indicated that genomic instability is a common feature of 
SHH-MBs with mutant TP53, but the initial characterization of p53R172P showed retention 
of p53-associated chromosomal stabilization, as well as cell cycle arrest activity (Liu et. 
al., 2004, Jones et. al., 2012). I sought to understand the role genomic stability might play 
in MB formation, and therefore founded primary cell lines from Ptch1p53∆E5-6 and 
Ptch1p53∆/R172P (Figure 14A). Karyotyping of these cell lines indicated that the 
chromosome of murine Ptch1+/- SHH-MBs, regardless of p53 status, had minimal 
genomic alterations and did not give evidence of chromosomal alterations, indicating that 
the potential role of p53R172P with regards to chromosomal stability is unlikely to be the 
source of the observed rescue (Figure 14B-C). Although chromosomal alteration was 
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observed in cell lines, incidence of aneuploidy was equivalent between both Ptch1p53∆E5-6 
and Ptch1p53∆/R172P. Based on these data, I reject the p53R172P function of increased 
genomic stability as the mechanism explaining delayed MB progression and propose that 
partial activation of p53’s cell-cycle arrest function is the primary mechanism responsible 
for the decreased rate of tumor onset in the Ptch1p53∆/R172P models.  
2.3 Summary 
To summarize these results, my major findings in this chapter are the 
demonstration of p53’s role in limiting a rare population of stressed GCPs during 
cerebellar development and the capacity for p53-mediated apoptosis to target retained 
SHH-MB during tumor initiation, thereby preventing the formation of MB in the 
presence of wild type p53. Using the p53∆E5-6 mutant allele, I was able to mark stressed 
cells that would normally not be visible due to the p53-Mdm2 negative feedback loop. 
Introduction of even a single functional allele of p53 was sufficient to drastically reduce 
the frequency of this p53∆E5-6-positive cell population in the EGL. However, this 
population of p53-positive cells did not expand, and appeared to be driven out of the cell 
cycle by p53-independent mechanisms. Only after the Ptch1+/- allele was introduced to 
this model was it possible for p53-positive cells to expand into p53-positive clusters, 
suggesting that Hedgehog pathway hyper-activation was capable of driving growth in a 
population of p53-activation sensitive GCPs. These clusters were capable of disrupting 
normal differentiation in the EGL, indicative of an oncogenic transformation in p53-
sensitive GCPs in response to Hedgehog pathway disruption. Characterization of these 
p53-positive clusters revealed that the majority of clusters were labeled by stem cell 
marker Sox2. These results show that the Hedgehog pathway is partially responsible for 
maintenance or dedifferentiation of stem-like cells in the EGL, although the process is 
not clear from these results, and that p53 is responsible for eliminating those cells if they 
exist outside of a brief window.  
Following cerebellar maturation, PNLs were visible in cerebella from all three 
models, but the frequency of PNL formation was approximately 4 times greater in 
Ptch1p53∆E5-6 and Ptch1p53∆/R172P models compared to the Ptch1p53WT model. Further, the 
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average size of clusters observed in the Ptch1p53∆E5-6 and Ptch1p53∆/R172P models was 
greater than the Ptch1p53WT model. In attempting to define a mechanism for these 
differences after development, I investigated the behavior of PNLs from each model, and 
demonstrated that increased apoptosis was detected in PNLs in the Ptch1p53WT model, 
supporting the role of apoptosis in preventing SHH-MB formation. Further, complete 
penetrance of Ptch1p53∆/R172P model revealed that retained cell cycle arrest function was 
insufficient to prevent the formation of SHH-MBs, showing nearly 100% tumor 
penetrance. These results demonstrate that only in the case of wild type p53 function was 
it possible for abnormally retained EGL cells to be effectively targeted, and that p53-
mediated apoptosis was the mechanism by which p53 prevents SHH-MB formation.  
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Figure 5: The p53∆E5-6 protein is accumulated in tumors 
(A) Structure of the TP53DBD-DNA complex. TP53-exon 5 is colored in cyan; exon 6 is 
colored in blue; two small in-frame deletions observed in human GBMs are colored in 
orange and purple, respectively; and a hot-spot residue R175 in exon 5 is colored in 
red. DNA is shown in yellow. 
 (B) p53ΔE5-6/ΔE5-6 glioma cell lines were infected with p53-specific siRNAs (p53si1 and 
p53si2) or mismatched siRNA (p53si1*) containing lentiviruses or control lentivirus (LT-
Con). Western blot analysis was performed using the cell lysates with the indicated 
antibodies. Irradiated p53WT spleen was used as positive control for p53 protein. 
(C) p53ΔE5-6/ΔE5-6 mouse glioma cell lines were infected with Mdm2-overexpressing GFP-
lentivirus (LT-Mdm2) or control GFP-virus (LT-Con). Cell lysates were analyzed by 
western blot analysis with the indicated antibodies.  
 (D) Co-immunoprecipitation assay of MDM2 and Flag-tagged TP53 WT or mutant-
TP53 proteins (TP53R175H, TP53ΔE5-6, TP53ΔDBD). HEK293T cells were co-transfected with 
the indicated plasmids. Cell lysates were immunoprecipitated with anti-Flag antibody, 
and probed with anti-MDM2 antibody. * Non-specific band. 
 (E-F). Flag-tagged wt-TP53 and mutant-TP53 constructs were co-transfected with or 
without MDM2 plasmid in human cell lines, HEK293T cells (E) or HCT116 TP53-/- cells 
(F). Cell lysates were subjected to western blotting analysis with the indicated antibodies. 
DBD, DNA-binding domain; WT, wild type; ML: molecular layer, IGL: internal granular 
layer. 
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Figure 6: Abnormal cells are observed in developing cerebellum 
(A) Immunohistochemistry of P8 cerebella, showing EGL at folia 8/9, indicates p53+ 
cells. Hi magnification of boxed region shown to the right. Arrows indicate p53 positive 
cells indicated by arrows, and p53 positive cell cluster is labeled. 
(B) Penetrance of p53+ cells and clusters in postnatal cerebellum. 
(C) Quantification of p53+ cells in control and mutant EGL. Each point represents a 
separate sample, with bars indicating Mean + SEM. 
(D) Quantification of p53+ cells in the ML and IGL of p53WT, p53∆E5-6 Ptch1p53∆E5-6, 
Ptch1p53∆/R172P and Ptch1p53WT models. 
EGL: External Granular Layer, ML: molecular layer, IGL: internal granular layer. 
Hematoxylin was used as a counterstain. Scale bars represent Mean ± SEM. Scale, 100 
um. 
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Figure 7: Clusters of abnormal cells are observed in the p53 mutant 
(A) Co-localization of Ki67 and p53 in P8 EGL (upper three images) and p53+ cell 
cluster (bottom image). Arrows indicate co-localized cells, arrowheads indicate 
p53+;Ki67- cells, and the white dotted line highlights to boundary of oEGL to iEGL. 
Insets show a p53+ and a co-localized cell within the oEGL. Insets at bottom show co-
localization in a p53+ cell cluster.  
(B-C) Quantification of proliferative cells in control iEGL and oEGL (B) and 
proliferative frequency in the p53+ cell population of EGL and p53+ cell clusters (C). 
(D) Co-localization of NeuN and p53 as well as Ki67 and p27 from adjacent sections of 
EGL and p53+ cell cluster. Dotted yellow lines demonstrate normal iEGL and oEGL 
layers. Purple dotted line indicates iEGL layer without NeuN expression. 
DAPI was used as a counterstain. Scale bars represent Mean ± SEM. Scale, 100 um. **, 
p< 0.01. 
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Figure 8: Abnormal cells discovered in developing cerebellum bear stem cell marker 
Sox2 
(A) Co-localization of Sox2 and p53. Arrows indicate co-localization, arrowheads 
indicate Sox2-positive; p53- cells, and the dotted line highlights the EGL. Boxed region 
shown at high magnification below. 
(B) Immunofluorescent co-labeling of Sox2 and Ki67 within P8 CB. Note that adjacent 
sections reveal that the Sox2-positive cluster in the Ptch1p53∆E5-6 model correspond with 
a p53-positive cell cluster. Dotted line indicates the boundary of the EGL, as defined by 
DAPI. 
(C) Immunofluorescent co-labeling of Sox2 and BLBP as well as Sox2 and NeuN within 
P8 CB. The Sox2-positive cluster in the Ptch1p53∆E5-6 model correspond with a p53-
positive cell cluster. 
(D) Immunofluorescent co-labeling of p53 and Nestin within a p53-positive cell cluster 
from the Ptch1p53∆E5-6 model.  
DAPI was used as a counterstain. Scale bars represent Mean ± SEM. Scale, 100 um. 
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Figure 9: Pre-neoplastic lesions are eliminated by p53-mediated apoptosis 
(A) H&E staining of representative P22 cerebella. Boxed regions are shown magnified 
below. Dotted lines indicate boundary of preneoplastic lesions.  
(A’) Quantification of total PNL area (mm2). Each point represents an individual sample. 
Area was assessed in two matched locations for each mutant.  
(A’’) Number of discrete PNL observed per sample. 
(B) Representative immunohistochemistry images of cleaved Caspase-3 in P22 PNLs. 
Arrowheads indicate positive cells. Insets show positive cells at high magnification. 
(B’) Quantification of the frequency of cleaved Caspase-3. 
(C) Immunofluorescenct labeling of Ki67 in postnatal day 22 (P22) Ptch1p53∆E5-6, 
Ptch1p53∆/R172P and Ptch1p53WT PNL. 
(C’-C’’) Quantification of absolute number of proliferative cells (C’) as well as frequency 
of proliferation (C’’). 
(D) Immunofluorescenct co-labeling of Sox2 and Ki67 in postnatal day 22 (P22) 
Ptch1p53∆E5-6, Ptch1p53∆/R172P and Ptch1p53WT PNL. 
PNL: Pre-neoplastic Lesion, DAPI was used as a fluorescent nuclear counterstain. Scale 
100 um. Error bars represent Mean ± SEM. Unpaired, two-tailed students T-Tests were 
used to determine p-values.   
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Figure 10: p53-mediated cell cycle arrest delays MB progression 
(A) Whole mount and (B) H&E images were taken from representative brains of 
Ptch1p53∆E5-6, Ptch1p53∆/R172P, and Ptch1p53WT models at P46. (B) Images shown 
represent multiple images for the Ptch1+/-p53∆E5-6 model. 
(A’) Quantification of the mean cerebellar area of each model at midline. 
(B’) Quantification of the total size of PNLs and MBs from each brain. 
(C) Penetrance of PNLs and MBs at P22 and P46 for each mutant model. 
(D-D’’) Representative images of co-labeling of Ki67 and p27, a marker of cell cycle 
arrest and differentiation during cerebellar development, in P46 PNL and/or MB. 
Quantification of the frequency of proliferation (D’) and frequency of cell cycle 
arrest/differentiation (D’’). 
PNL: Pre-neoplastic Lesion, ML: molecular layer, IGL: internal granular layer. DAPI 
was used as a counterstain. Scale bars represent Mean ± SEM. Scale, 100 um. 
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Figure 11: Pre-neoplastic lesions are capable of progressing without p53 activation 
(A, D) Immunohistochemistry of p53 identified negative PNL found in P22 (A) and P46 
(D) mutants. Adjacent sections were labeled for Ki67 to demonstrate proliferative activity 
in PNLs and MBs.  
(B, E) Frequency of p53 positive and p53 negative clusters were qualitatively assessed 
for p22 (B) and P46 (E).  
(C, F) Frequency of p53+ cells in P22 PNL (C) and P46 PNL and/or MBs (F). Each point 
represents a discrete lesion.  
Scale, 200 um, Error bars represent Mean + SEM. Fishers exact test was used to 
determine p-value in B and E. Unpaired, two-tailed students t-tests were used to 
determine p-values in C and F. 
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Figure 12: p53-mediated apoptosis is required to prevent MB 
(A) MB-free curve of Ptch1p53∆E5-6, Ptch1p53∆/R172P, and Ptch1p53WT models. (p, Log-
rank (Mantel-Cox) test) 
(B) Tumor Penetrance in the Ptch1p53∆E5-6, Ptch1p53∆/R172P and Ptch1p53WT. 
Asymptomatic mice were kept for a minimum of 1-year prior to sacrifice. 
(C) Anatomical location of MBs arising in mutant models. 
(D) Kaplan-Meier survival curve of Ptch1p53WT/WT, Ptch1p53WT/∆E5-6 and Ptch1p53WT/R172P 
models following the long-term IR treatment scheme. Log Rank test (Mantel-Cox) was 
used to determine p-value. 
(E) Representative H&E images of MBs from each Ptch1 model, showing dense, purple 
tumors characterized by frequent mitotic figures (Arrowheads) and nuclear molding 
(Arrows). 
(F) Immunohistochemistry images of Ki67 and Cleaved Caspase-3 taken from 
Ptch1p53∆E5-6, Ptch1p53∆/R172P and Ptch1p53WT MBs. Quantification of Ki67 (F’) and 
Cleaved Caspase-3 (F’’) frequency in MBs, showing no significant difference in 
proliferative or apoptotic cells between MB models. Scale bar, Ki67 200 um, CCasp3,100 
um. 
 (G) Representative immunohistochemistry images taken from Ptch1p53∆E5-6, 
Ptch1p53∆/R172P and Ptch1p53WT MBs, demonstrating presence of Synaptohpysin, GFAP, 
Nestin, and Olig2. Arrowheads indicate tumor cells associated with GFAP. Scale bars, 
100um 
 
 
 
 
 61 
 
 
  
 62 
Figure 13: Activation of the hedgehog pathway is independent of p53 function 
(A) Genotyping MB samples from Ptch1p53∆E5-6, Ptch1p53∆/R172P and Ptch1p53WT mice, as 
well as primary cell lines from Ptch1p53∆E5-6 and Ptch1p53∆/R172P, to determine the 
presence of wild type Ptch1, using probes covering exons 2-3 or exons 7-9. Exon 2-3 is 
lost in the germ-line null Ptch1. Normal brain tissues of p53WT mice were used as a 
positive control.  
(B) Quantitative PCR was used to determine the ratio of Ptch1 wild type to total, using 
probes covering exons 2-3 or exons 7-9. Exon 2-3 is lost in the germ-line null Ptch1. 
Samples with ratios below 0.2 matched samples qualitatively assessed as LOH. Negative 
control, represented by a ratio of 1.0, was provided by tissue from p53WT model CB. 
(C) Quantitative RT-PCR of Hedgehog pathway targets Gli1, Gli2, N-Myc and Ptch1, 
using MBs from Ptch1p53∆E5-6, Ptch1p53∆/R172P and Ptch1p53WT mice, and normalized 
against adult CB from p53WT littermates. No difference was detected in downstream 
target expression between LOH and non-LOH samples. 
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Figure 14: Acquisition of chromosomal defects does not directly correspond to p53 
status  
(A) Primary cell lines were developed using MBs from Ptch1p53!/!E5-6, Ptch1p53!/R172P 
and Ptch1p53WT mice and grown in serum free, non-adherent conditions prior to light 
microscopy imaging. 
(B-C) Cell lines were used to demonstrate chromosome number from Ptch1p53!E5-6 and 
Ptch1p53!/R172P models using (B) metaphase spread techniques. (C) Quantification of 
chromosome number from multiple low passage (< 2) cell lines from the Ptch1p53!E5-6 
and Ptch1p53!/R172P models. Each point represents a single cell. 
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Chapter III: Radiation Activates p53 Above a 
Threshold Required to Target p53 wild type MB  
3.1 Introduction 
Despite relying on the same developmental pathway to drive tumor growth, SHH-
MBs with wild type and mutant TP53 are fundamentally different (Jones et. al., 2012, 
Zhukova et. al., 2013). SHH-MBs arise from granule cell precursors (GCPs), which 
depend on Hedgehog signaling for rapid proliferation and expansion during the 
development of the cerebellum (Oliver et. al., 2005, Yang et. al., 2008). In contrast to 
TP53 wild type SHH-MBs, which frequently carry PTCH1 or SUFU mutations, TP53-
mutant SHH-MBs often harbor amplification of downstream targets of the Hedgehog 
pathway, such as N-Myc and Gli2, potentially rendering these tumors resistant to 
inhibitors of Smoothened (Smo) receptor (Schuller et. al., 2008, Yang et. al., 2008, 
Northcott et. al., 2010, Kool et. al, 2014). Furthermore, TP53-mutant SHH-MBs are 
frequently associated with large cell/anaplastic histology and exhibit an increased chance 
of gaining secondary mutations, as well as an increased chance of chromothripsis 
(Rausch et. al., 2012, Jones et. al., 2012). These observations suggest SHH-MBs form 
along two distinct paths depending on the p53 response of the GCP population.  
Upon oncogenic activation of SHH signaling, the cell response is controlled in a 
temporal manner, with a limited window during which cells do not respond to stress by 
activating p53 (Pazzaglia et. al., 2006, Tanori et. al., 2013). Embryonic stem and granule 
cell precursors (GCP) do not activate the p53 response following radiation-induced DNA 
damage, but GCP p53 activation increases during postnatal development, displaying 
widespread p53 activation and associated apoptosis in postnatal day 10, thereby 
preventing SHH-MB formation (Pazzaglia et. al., 2006). Therefore, in order for MBs to 
arise with a sporadic p53 mutation, p53 inactivation must occur in the germline or during 
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embryonic development, providing a permissive context that allows the survival of highly 
aggressive tumor cells with high levels of genomic instability. On the other hand, p53 
wild type GCPs maintaining the p53 response of embryonic cells fail to activate the p53 
response above a threshold sufficient to require disruption of TP53 form without 
disrupting the p53 response(s), which can be activated in response to radiation and 
chemotherapy. It remains unknown which p53-mediated responses, cell-cycle arrest, 
senescence or apoptosis, eliminate tumor susceptible GCPs during the initiation and 
progression of TP53-mutant SHH-MB formation. During cerebellar development, Sox2-
positive stem cells of the rhombic lip give rise to Math1+ granule cell precursors 
migrating from the rhombic lip into the EGL, losing Sox2 expression as they differentiate 
(Yang et. al., 2008, Pazzaglia et. al., 2013). Recent evidence has implicated that Sox2 
also marks a quiescent stem-like population located in SHH-MBs, and these cells have 
been implicated as a population responsible for MB treatment resistance and recurrence 
(Ahlfeld et. al., 2013, Vanner et. al., 2014). A rare and quiescent cancer stem cell-like 
population in SHH-MBs, characterized using early lineage markers, such as Sox2, are 
resistant to chemotherapy and can generate recurrent tumors both in vitro and in vivo. It 
remains unknown whether the resistance to chemotherapy of Sox2-positive MB-stem 
cells is caused by insufficient activation of p53-mediated responses upon radiation and 
chemotherapy, leading to tumor recurrence. 
In this chapter, I demonstrated that p53 remains a viable therapeutic target in MBs 
and PNLs that form within the Ptch1p53WT model. Making use of ionizing radiation to 
put stress on MBs, I showed that p53 wild type MBs activated p53 response and thereby 
induced p53-mediated apoptosis. By characterizing the cells of the deficient regions, I 
identified a Sox2-positive subpopulation present in the wild type p53 SHH-MB able to 
avoid p53-mediated apoptosis. Having determined that the reactivation of p53 is capable 
of targeting mature SHH-MBs, I next sought to understand whether the developing PNLs 
were able to bypass p53 during development by maintaining p53 signal below a critical 
threshold. Treating developing lesions with a clinically relevant radiation dose, I revealed 
a reduction in p53 wild type and heterozygous SHH-MB penetrance in response to p53-
mediated apoptosis, and also demonstrated that p53-mediated cell cycle arrest is 
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insufficient to effectively target Sox2-positive cells, although it induces differentiation 
response in other PNL cells. Finally, I found that IR treatment is capable of inducing 
alterations to the p53 pathway, leading to loss of heterozygosity within Ptch1p53 
heterozygous mutants. This chapter serves to demonstrate that p53 activation is a viable 
target within those SHH-MBs that arise with the majority of the p53 pathway intact, and 
elucidates the role the distinct p53 pathway responses play in MB cells. 
3.2 Results 
3.2.1 MB formed in the Ptch1 background do not require p53 pathway 
inactivation 
In order to explore the possibility of tumors forming without requiring mutation to 
p53 or inactivation of the p53 pathway, I began by collecting samples from Ptch1p53∆E5-6 
(hGFAP-Cre;Ptch1+/-;p53E5-6/E5-6), Ptch1p53∆/R172P (hGFAP-Cre;Ptch1+/-;p53R172P/E5-6) and  
Ptch1p53WT (Ptch1+/-;p53E5-6/E5-6) MBs, in order to confirm the retention of the p53 allele 
in SHH-MBs (Figure 15A-B). Due to impurities within the collected tissue samples, 
recombination efficiency was unclear (Figure 15B), so I also created primary MB cell 
lines, and used these cell lines to confirm the complete recombination of p53∆E5-6 in the 
Ptch1p53∆E5-6 (n = 7/7) and Ptch1p53∆/R172P (n = 7/7) MBs (Figure 15C). Tissue cultured 
from Ptch1p53WT was unable to form primary cell lines that remained viable after 3-5 
weeks (n = 0/6). Having eliminated the possibility of chromosomal loss as a potential 
mechanism by which these tumors were capable of forming without p53 stabilization, I 
next investigated the question of whether additional mutations may have occurred within 
the p53 alleles and thereby allowed MB progression. Sanger sequencing carried out by a 
third party source failed to find any additional mutations within 7 Ptch1p53WT tumors, as 
well as finding no novel mutations within 5 Ptch1p53WT/R172P (Ptch1+/-;p53R172P/E5-6) and 6 
Ptch1p53∆/R172P MBs, though the expected G515C mutation was detected (Figure 15D-
D’). Deep sequencing conducted by collaborator Chaoyang Li found that in 1 of the 7 
Ptch1p53WT tumors, a p53 mutant subpopulation existed, and accounted for 15.6% of 
total cell population (data not shown). The presence of accumulated p53 was confirmed 
both on tissue and through western blot, with elevated p53 detected in both Ptch1p53∆E5-6 
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and Ptch1p53∆/R172P (Figure 15E-F). In spite of elevated levels of p53R127P in the 
Ptch1p53∆/R172P model, only 1 of 17 samples showed accumulation of p53 target p21 
(Figure 15F). Curiously, although the p53 antibody was demonstrated to have affinity for 
both wild type and mutant p53 (Figure 5B), detected level of p53R172P was notably higher 
in the Ptch1p53∆/R172P models, indicating that p53R172P might be preferentially stabilized 
(Figure 15F). These results demonstrate that p53 is not targeted during the formation of 
MBs, and remains a viable therapeutic target. 
3.2.2 Radiation-induced stress on MB activates the p53 pathway 
Having observed that PNLs are fully capable of progressing to MBs without 
inducing p53, I next sought to determine the differential therapeutic effect observed 
between SHH-MBs in the context of wild type and mutant p53. In order to elevate p53 
activation, animals exhibiting hydrocephalus and brain tumor associated neurological 
symptoms were treated with 20 Gray of radiation to the head and neck, and chased for 4 
hours prior to tissue collection. Within the Ptch1p53WT model, widespread apoptosis, as 
represented by cleaved caspase-3, and reduced proliferation, as assessed by Ki67, were 
observed 4 hours after treatment (Figure 16A). Within the Ptch1p53∆/R172P model, 
apoptotic cell frequency was not increased compared to Ptch1p53∆E5-6, but a limited p53-
independent apoptotic effect was observed in both models (Figure 16A-A’). Curiously, 
radiation was capable of inducing a limited cell cycle arrest response, showing reduced 
proliferation in non-apoptotic cells of both Ptch1p53∆/R172P and Ptch1p53WT (Figure 
16A’’). Protein was extracted from these tissue and it was demonstrated that, where p53 
was expressed in the Ptch1p53∆E5-6 and Ptch1p53∆/R172P models even without radiation, it 
was only with the elevated level of p53 activation following radiation that p53R172P was 
able to promote it’s downstream targets, including the cell cycle arrest protein p21 
(Figure 15F’). This matched with results obtained using quantitative RT-PCR, 
demonstrating that after radiation therapy, both apoptotic target Puma and cell cycle 
arrest target p21 were elevated (Figure 16B). Although differential proliferation and 
apoptosis was not demonstrated in the Ptch1p53∆E5-6 model at 4 hours after radiation, a 
response was seen 24-hours after treatment with 4 centigray (cGy) radiation, resulting in 
decreased proliferation in both Ptch1p53∆E5-6 and Ptch1p53∆/R172P (Figure 17A-B). 
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Curiously, although the p21 response was only visible by western blot 4 hours after IR, 
p21 was stabilized in many cells of the Ptch1p53∆/R172P model 24 hours after radiation. 
Based on these data, it is evident that elevated p53 activation is sufficient to induce a 
potent p53 response, but that without the presence of wild type p53, the radiation 
response will be insufficient to effectively treat MB.  
3.2.3 The Sox2-positive subpopulation of MB cells is treatment-resistant 
As I have demonstrated that Sox2-positive cells were present even at early stages 
of MB development (Figure 9D), I next attempted to determine the p53 response of the 
Sox2-positive MB population. Similar to the behavior of Sox2-positive cells found in 
PNLs, I demonstrated that Sox2-positive cells within MBs were rarely labeled with p53, 
and while the frequency of p53 positivity was marginally higher within both the 
Ptch1p53∆E5-6 and Ptch1p53∆/R172P models, the presence of mutant p53 did not lead to a 
drastic increase in p53 frequency (Figure 18B). However, following 20 cGy radiation 
dose followed by a 4-hour chase, many Sox2-positive cells express p53. The frequency 
with which p53 and Sox2 colocalized following a low dose, 4 gray radiation treatment 
was significantly elevated compared to , and showed a widespread induction of p53 in all 
groups, but most prominently within the Ptch1p53WT model, where 88% of Sox2-positive 
cells would activate p53 at high levels following radiation (Figure 18A). Surprisingly, 
many Sox2-positive cells remained p53 negative following stimulation in both the 
Ptch1p53∆E5-6 and Ptch1p53∆/R172P models, indicating that the p53 response of Sox2-
positive cells is not a homogenous response, and likewise that Sox2-positive cells are 
able to at least partially avoid p53 activation in times of stress (Figure 18B). Although my 
previous observations indicated that overall proliferation decreased following the 
activation of p53 (Figure 17A-B), I found that the proliferation frequency of Sox2-
positive cells remained unchanged following radiation treatment, although proliferative 
Sox2-positive cells in the Ptch1p53WT model were rare regardless of treatment, limiting 
the potential effect of any p53 response (Figure 19A-C). Likewise, in the Ptch1p53∆/R172P 
model, but not Ptch1p53∆E5-6 or Ptch1p53WT, p27 positive cells were present following 
radiation, but the p27 positive cells did not colocalize with Sox2, once again indicating 
that Sox2 is likely a treatment-resistant population lacking a complete p53 response 
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(Figure 19C). These results show that although the majority of MB cells are p53-
activation sensitive in the presence of wild type p53, the Sox2-positive cell population is 
a privileged stem-like population, frequently quiescent throughout MB progression and 
resistant to activation of p53-mediated apoptosis.  
3.2.4 Irradiation of PNLs reduces tumor burden in p53WT SHH-MB 
By treating MBs arising in symptomatic animals, I was able to elicit a strong p53-
mediated apoptotic response, demonstrating that therapeutic value of p53 in developed 
tumors. To determine whether p53 activation was below a critical threshold within the 
retained GCPs of the Ptch1p53WT PNL, I administered a clinically relevant course of 
radiation at the rate of 2 centiGray (cGy) per day, beginning the week after postnatal 
cerebellar development (P22-P24) and continuing for two 5-day courses, before 
specimens were collected at one of three times, either at 24 hours after the final radiation 
dose, to demonstrate an acute radiation response, at postnatal day 46, thereby 
demonstrating the impact on MB progression compared to untreated samples, and in 
SHH-MBs, determining differential survival in mutant models (Figure 20A).  I analyzed 
specimens taken 24 hours post radiation treatment and found that PNLs within specimens 
from each of the aforementioned models were smaller than those observed at P22 (Figure 
20B-C). However, while all three models were reduced in PNL area, though not in the 
number of PNLs compared to what was observed at P22, the number of proliferative cells 
in PNL of both Ptch1p53∆/R172P (n = 5) and Ptch1p53WT (n = 5) was reduced, with most 
PNLs featuring less than 10 proliferative cells, whereas the Ptch1p53∆E5-6 model retained 
a proliferative population (Figure 20B, 21C). Further, unlike Ptch1p53∆/R172P PNLs at P22, 
where a mixture of high and low p53 lesions were observed (Figure 11A), all PNLs 
within the P35 treated cerebella lacked p53 stabilization (Figure 20B, 20B’). While cells 
with the dense, rounded bodies characteristic of granular neurons are not found in 
untreated PNL from both Ptch1p53∆E5-6 and Ptch1p53∆/R172P, although occasionally present 
in untreated Ptch1p53WT PNL, I found that cells with the morphology of granular neurons 
was heightened in all three models following radiation, with the majority of cells 
adopting this morphology in almost all p35 PNLs from the Ptch1p53∆/R172P and 
Ptch1p53WT models (Figure 20C-C’). Even within proliferative PNL from the 
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Ptch1p53∆E5-6 model, I identified small clusters of non-proliferative cells with IGL-like 
morphology (Figure 20B, 20C’). These observations demonstrate that irradiation of PNLs 
is capable of inducing a potent inhibitory effect on pre-neoplastic lesions, inducing a cell 
cycle arrest and differentiation response even in the presence of reduced p53 activity, as 
demonstrated by Ptch1p53R172P. Curiously, a potent p53-independent radiation response 
was observed in the Ptch1p53∆E5-6 model, effectively debulking the lesion without 
effectively eliminating the proliferative cell population. 
I next investigated the role cell cycle arrest and differentiation played on the 
PNLs, and found that while cells of PNL from the Ptch1p53∆E5-6 model were often p27 
positive, indicative of cell cycle arrest, they were rarely NeuN positive, with only a 
handful of NeuN positive cells in or adjacent to the ML (Figure 21A). Within the 
Ptch1p53∆/R172P and Ptch1p53WT models, almost all p27 cells found in PNLs co-labeled 
with NeuN, indicative of differentiated neurons, a process reminiscent of GCP 
differentiation and migration as would be observed during cerebellar development. 
Moreover, within Ptch1p53∆/R172P, a large number of P27/NeuN positive cells were 
located within the molecular layer, demonstrating that cells not only converted into 
granular neurons, but also migrating toward the IGL in response to p53 activation. 
However, in spite of the success in reducing PNL size and proliferation, the Sox2-
positive population only responded to radiation treatment within the Ptch1p53WT model 
(Figure 21B, 21D-D’). This demonstrated that Sox2-positive cells, in addition to resisting 
p53-mediated apoptosis at end stage, are also capable of avoiding the p53-mediated cell 
cycle arrest response. Although there was little evidence of Sox2-positive cell 
differentiation, Sox2-positive cells remained largely quiescent (Figure 21E). These 
observations, taken together, indicate that, within the SHH-MB model, p53-stimulation 
was capable of inducing a p53-mediated response capable of both removing abnormal 
cells, as indicated by reduced PNL size, and causing initiation of a differentiation 
process, as shown through the transformed morphology of the PNL cells.  
 71 
3.2.5 Sox2-positive cells in PNLs are targeted by p53-mediated apoptosis but 
not cell cycle arrest 
I next sought to understand the long-term reaction of PNL to radiation treatment, 
and therefore collected PNLs found within treated CB at postnatal day 46, and inspected 
the size of the cerebella. I found that within all three models, the area of PNLs was 
reduced compared to untreated P46 (Figure 22A). I used each of the models to 
demonstrate different facets of radiation response, both through p53-dependent and 
independent mechanisms, to fully explore the PNL treatment response. I found that the 
greatest reduction in PNL area (85%) was observed within the Ptch1p53∆E5-6 model, 
demonstrating a strong p53-independent radiation response (Figure 22B, B’). Likewise, 
there was a 65% reduction in PNL area in untreated Ptch1p53∆/R172P, demonstrating the 
p53-mediated cell cycle arrest activity response when stimulated (Figure 22B’’). Within 
the Ptch1p53WT model, only a marginal reduction following the prolonged treatment was 
observed, indicating that the p53-mediated apoptotic response is already capable 
eliminating many of the PNLs, however, small proliferative lesions were still observed in 
the Ptch1p53WT model following the therapeutic course (Figure 22B’’’). With these three 
models, a stepwise response to radiation-induced stress was identified, both in a p53 
dependent and independent fashion. Based on the observed reduction in size, I sought to 
demonstrate whether proliferation was likewise reduced compared to untreated 
specimens (Figure 22D-E). Surprisingly, I found that in both Ptch1p53∆E5-6 and 
Ptch1p53∆/R172P models, the proliferation rate was radically increased in PNLs after 
treatment, whereas proliferation remained infrequent in the Ptch1p53WT model (Figure 
22E). These results show an unexpected tumor purification process within the treated p53 
mutant tumors, showing a drastically enriched proliferative population.  
Based on the reduced PNL size and increased proliferation, as well as my 
observations from the acute treatment response, I proposed a model in which radiation-
induced stress was sufficient to selectively remove non-proliferative cells from the tumor 
mass but fails to target the quiescent Sox2-positive niche, which is capable of reforming 
into highly proliferative PNLs, mimicking the proposed recurrence of MBs following 
treatment. I found that proliferative Sox2-positive cells were drastically enriched within 
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the Ptch1p53∆/R172P model, unlike the Ptch1p53∆E5-6 model, unchanged by treatment, or the 
Ptch1p53WT model, where Sox2-positive cells remained quiescent (Figure 23A-B). I next 
determined that p53 was not a prominent label in these Sox2-positive cells, indicating 
that, in spite of the more frequent proliferation, these cells more resembled the Sox2-
positive population observed in PNLs and MBs, not those previously described as 
existing during cerebellar development (Figure 23C-D). Curiously, the enriched 
proliferation observed in Sox2-positive cells of the treated PNL did not persist into SHH- 
MBs, where Sox2-positive cells were once again quiescent (Figure 24E). Similar to PNL, 
apoptosis was a rare process though apoptotic cells were observed in all models, 
regardless of p53 mutation (Figure 22C). These observations indicate that radiation 
treatment efficacy is largely determined by the status of p53 in the MB models, but that 
only when p53 activation surpasses a critical threshold is it possible to efficiently target 
all cell populations. Otherwise, a p53-activation resistant population, including Sox2-
positive stem-like cells, will remain, evading treatment and potentially leading to tumor 
recurrence.  
3.2.6 Radiation treatment of MB requires wild type p53 
Based on these results, I next sought to determine whether the radiation treatment 
was successfully preventing tumor formation. I began by collecting samples that had 
been given the same treatment described, but allowed mice to progress until they 
demonstrated neural symptoms (Figure 24A, 24C). Unsurprisingly, I found that within 
the Ptch1p53WT model, tumor penetrance was reduced from 38% to 12% as a result of the 
treatment protocol, as well as increasing median survival by 28 days, and a similar 
response within the Ptch1p53WT/R172P model, which sees a decline from 44% to 10% 
penetrance (Figure 24A-B). On the other hand, I observed minimal alterations to the 
Ptch1p53∆E5-6 and Ptch1p53∆/R172P models, with no change in penetrance and an eleven and 
two day increase in median life, respectively. Each model produced MBs featuring 
histological hallmarks of human MB, and these tumors were aggressive with high 
frequency of proliferation, much like MBs forming without treatment (Figure 24C-E). 
Unlike recent publications that suggested frequent mutation to p53 can be found in 
recurrent SHH-MBs (Hill et. al., 2015, Tamayo-Orrego et. al., 2016), I found that p53 
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protein was not detectable within irradiated Ptch1p53WT model, although it was present at 
high frequency in tumors arising from Ptch1p53WT/R172P (Figure 25A). In order to further 
explore this question, I isolated p53 from the Ptch1p53∆/R172P, Ptch1p53WT and 
Ptch1p53WT/R172P models, and submitted the isolated p53 for Sanger sequencing, which 
found no additional mutations within the p53WT allele. While I was unable to find 
mutations to the p53 allele, I did demonstrate that, in both instances of MBs arising 
within Ptch1p53WT/R172P, p53 underwent loss of heterozygosity following treatment, 
thereby providing a model mimicking recurrent SHH-MBs (Figure 25B). These result 
provide evidence that p53 signaling is eliminated following selective pressure in SHH-
MBs, and suggests that wild type p53 SHH-MBs do not activate p53 in response to 
oncogenic stress during tumor progression. 
3.3 Summary 
In this chapter, I have investigated the response of MBs and PNLs to p53 
activation, attempting to elevate p53 response sufficiently to impede SHH-MB formation 
in the presence of wild type p53. The majority of SHH-MBs in humans arise without 
mutation to TP53 (Zhukova et. al., 2013), indicating they originate from a TP53-
activation resistant cell population, thereby remaining below the level of activation 
capable of responding to oncogenic stress. However, it was possible to increase the 
frequency of p53 activation within MBs, thereby activating a potent apoptotic response 
within those tumors retaining wild type p53. Further, treatment of PNLs was able to 
activate p53, eliciting a strong cell cycle arrest response and blocking SHH-MB 
formation, in this case sufficient to reduce MB penetrance to one-third of the frequency 
observed without treatment.  
These results provide a clear message regarding the rationale and efficacy of 
treatment in humans, demonstrating that the radiation response in SHH-MBs is mediated 
by p53. This stands in contrast to the mechanistic basis of radiation therapy in most other 
tumors, where radiation effects function in spite of inactivation of the p53 pathway, 
typically by inducing genetic damage that leads to mitotic collapse (Brachmann et. al., 
1993). The effective decline in tumor penetrance following clinically relevant doses of 
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radiation indicate that activation of the p53 response may be an effective target in SHH-
MBs, and should be investigated as soon as a viable therapeutic agent capable of 
activating p53 in the brain is developed. Surprisingly, I found that, although an p53-
independent decline in lesion size was observed following treatment, without the 
retention of wild type p53, the PNLs were only temporarily inhibited by radiation. In fact, 
treated lesions produced SHH-MBs with equivalent penetrance and little to no change in 
median survival in both the p53 mutant models. Further, treatment of PNLs within both 
the p53 mutant models resulted in the enrichment of proliferating cells, indicating a 
differential response to genotoxic stress amongst the cells of the PNLs, with some portion 
of non-proliferative cells removed and the remaining cells entering the cell cycle. This 
suggests that radiation treatment may in fact be detrimental within p53 mutant SHH-
MBs, inducing a debulking effect but not successfully targeting proliferative cells capable 
of tumor recurrence. 
My examination of the behavior of the Sox2 population of treated PNLs indicate 
that this differential response may arise in part as a result of the stem-like population, 
which appears to be capable of resisting partial p53 activation, as demonstrated with the 
retention of Sox2-positive cells in the Ptch1+/-p53∆/R172P model. This concept is reinforced 
by the minimal response to radiation observed in both the treated p53 models, which, in 
spite of receiving radiation dose equivalent to the wild type p53 tumor, saw no change in 
penetrance. These data suggest reduced p53 activity as a mechanism for resistance to 
therapy in Sox2-positive cells (Vanner et. al., 2014). As a quiescent population, it has 
been proposed that Sox2-positive cells are responsible for the recurrence of MB. Based 
on my data, I have shown that Sox2-positive cells are capable of surviving extreme 
radiation dose without activating the apoptotic response, and that these cells survive early 
treatment only to later reenter the cell cycle, indicating that Sox2-positive cells represent 
a means for SHH-MB recurrence. Sox2 specific therapy may be able to target the 
quiescent Sox2 population, but my data suggests that the Sox2 population may become 
vulnerable following radiation therapy, as an increased number of Sox2-positive cells 
enter the cell cycle following treatment. Further investigation into the Sox2 stress 
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response, which appears able to drive cells into the cell cycle, may provide insight into 
methods of treating this cell population. 
Taken together, this chapter demonstrates that the activation of wild type p53 
above a threshold is capable of eliminating disease. Activation of the p53 response 
resulted in widespread apoptosis and elimination of almost all proliferative cells in the 
presence of functional p53, with almost no response when p53 was lost. This p53 
activation was so potent that within p53 heterozygous tumors, the remaining p53 allele 
was lost, generating a p53 mutant tumor following radiation. This loss of p53 is 
reminiscent of the frequency of p53 mutation in recurrent human MBs, where the 
majority of recurrent MBs arise with inactivation of the p53 pathway (Morrissey et. al., 
2016). These data suggest that recurrent MBs should be approached using the same 
treatment methods that are applied to SHH-MBs with mutant p53, and further 
demonstrate the need to develop a robust treatment for MBs arising with mutant p53.  
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Figure 15: Inactivation of p53 is not Required for MB Formation  
(A-C) PCR using tail snip and mutant DNA confirms recombination of p53∆E5-6 within 
p53 mutant tumors (A), presence of p53R172P within p53 mutant tumors (B) and p53∆E5-6 
and confirms presence of p53R172P within primary cell lines (C). 
(D-D’) Sequencing of tissue from Ptch1p53∆/R172P confirms presence of p53R172P and no 
additional mutations to p53 (D). Sequencing of Ptch1p53WT fails to find any acquired p53 
mutation (N = 7, data not shown). Schematic showing the location of the p53R172P 
mutation, caused by G515C (D’).  
(E) Low and high magnification images of MBs from Ptch1p53∆E5-6, Ptch1p53∆/R172P and 
Ptch1p53WT model labeled with anti-p53 antibody, with hematoxylin counterstain. Scale 
bars represent 100 um. 
(F-F’) Immunoblotting of p53 and p21 protein levels in untreated MBs (F) and MBs 
collected 4 hours after treatment with 20 Gray  (F’). B-Actin was used as a loading 
control. 
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Figure 16: Radiation is Capable of Activating p53 in MB 
(A) Immunohistochemistry images of cleaved caspase-3, Ki67, and p53 in MBs collected 
4 hours after treatment with 20 Gray radiation.  
(A’) Quantification of apoptotic frequency, as assessed by Cleaved Caspase-3 in MBs 
from the Ptch1p53∆E5-6, Ptch1p53∆/R172P, and Ptch1p53WT models following radiation.  
(A’’) Quantification of proliferation frequency, as demonstrated by Ki67 staining of 
treated animals and littermate controls. 
(B) Quantitative RT-PCR determined expression of p53 targets PUMA, p21, and MDM2 
in untreated MBs and MBs collected 4 hours after treatment with 20 Gray. Fold change 
was normalized against untreated Ptch1p53WT MBs, and GAPDH was used as a control. 
Scale, 100 um. Error bars represent Mean ± SEM. Unpaired, two-tailed students T-Tests 
were used to determine p-values.  
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Figure 17: Radiation Activates both Apoptotic and Cell Cycle Arrest Responses 
(A) Histopathological analysis of MBs collected 24 hours following a 4 Gray radiation 
dose, labeling p53, Cleaved Caspase-3 and Ki67 in the Ptch1p53∆E5-6, Ptch1p53∆/R172P and 
Ptch1p53WT models.   
(B) Quantification of proliferation frequency from Ptch1p53∆E5-6 and Ptch1p53∆/R172P 
littermates, comparing proliferation between untreated MBs and MBs collected 24 hours 
after a 4 Gray treatment. 
(C) Histopathological analysis of MBs collected 24 hours following a 4 Gray radiation 
dose, labeling p21 in the Ptch1p53∆E5-6 and Ptch1p53∆/R172P models. The boxed region is 
shown enlarged in the inset. 
Scale bars represent 100 um. 
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Figure 18: Sox2 Positive Cells evade Radiation via Decreased p53 Response 
(A) Co-localization of cleaved Caspase-3 and Sox2 in MBs collected 4 hours after 
treatment with 20 centigray from the Ptch1p53∆E5-6, Ptch1p53∆/R172P and Ptch1p53WT 
models. Note that, in all three models, Sox2 rarely colabels with cleaved Caspase-3. Inset 
shows high magnification of boxed region. 
(B) Co-localization of p53 and Sox2 in representative images of P22 and P46 PNL, 
untreated MBs and treated MBs from the Ptch1p53∆E5-6, Ptch1p53∆/R172P and Ptch1p53WT 
models. DAPI counterstain is shown in P22 and P46 to delineate the boundary of the 
PNLs, whereas tumor images were all taken within the tumor mass. Arrowheads indicate 
colocalized cells.  
Scale bar depicts 100 uM. 
 
  
 83 
 
 84 
Figure 19: Sox2-positive cells maintain Quiescence through a p53-mediated 
Response 
(A) Co-labeling of Sox2 and Ki67 in P22 PNL from the Ptch1p53∆E5-6, Ptch1p53∆/R172P and 
Ptch1p53WT models. Note that co-localization is uncommon in all models. 
(B) Co-labeling of Sox2 and Ki67 in MBs from the Ptch1p53∆E5-6, Ptch1p53∆/R172P and 
Ptch1p53WT models.  
(C) Co-labeling of p27, Sox2 and Ki67 in MBs from the Ptch1p53∆E5-6, Ptch1p53∆/R172P 
and Ptch1p53WT models 4 hours after receiving 20 centigray irradiation. Arrows indicate 
co-localization of Ki67 and Sox2. 
DAPI was used as a nuclear counterstain. Scale bar depicts 100 uM. 
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Figure 20: Radiation Treatment of Pre-neoplastic Lesions Activates a potent p53 
response, inducing cell cycle arrest and differentiation 
(A) Graphical representation of long term treatment scheme, wherein mice were 
irradiated for 5 days given 2 rest days, and then irradiated 5 days more, beginning at P21-
23, and then mice were collected at one of three indicated time points, P35, P46, or upon 
MB associated neurological symptoms.  
(B) Images taken of H&E, anti-Ki67, and anti-p53 mutants from the Ptch1p53∆E5-6, 
Ptch1p53∆/R172P and Ptch1p53WT models collected 24 hours after the completion of long-
term IR treatment scheme, in which mice were subjected to a 2 Gray per day dose 
ionizing radiation for a total of 10 days beginning at P22-P23 and ending at P34-P35. 
Insets show high magnification of boxed regions. Scale bars show 200 um. 
(B’) Calculation of the frequency of p53 positivity in P35 treated PNLs, as calculated 
based on histology.  
(C) High magnification H&E images show cellular morphology, with the boxed region(s) 
shown below at increased magnification, demonstrate that cells of the IR treated PNL 
acquire dense rounded cell bodies, reminiscent of granular neurons, in the Ptch1p53∆E5-6, 
Ptch1p53∆/R172P and Ptch1p53WT models. Scale bars show 100 um. 
(C’) A qualitative analysis of PNL containing a majority of cells that morphologically 
resemble granular neurons, characterized by small, dense rounded nuclei. 
Error bars represent Mean + SEM. Unpaired, two-tailed students t-tests were used to 
determine p-values. 
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Figure 21: Sox2-positive cells are only elminiated by radiation in the presence of p53 
apoptotic response 
(A) Co-localization of p27 and NeuN in PNL following P21-P35 radiation treatment in 
order to assess senescence and differentiation of treated PNL in the Ptch1p53∆E5-6, 
Ptch1p53∆/R172P and Ptch1p53WT models. 
(B) Co-localization of Sox2 and Ki67 in PNL following P21-P35 treatment 
demonstrating the response of the Sox2-positive population to prolonged radiation.  
(C) Quantification of total number of proliferative cells (Ki67+) in treated P35 PNLs.  
(D-D’) Quantification of total number of Sox2-positive cells (D) and Sox2-positive cell 
frequency (D’) in treated P35 PNLs demonstrates retention in models without wild type 
p53. 
(E) Co-localization of Sox2 and Ki67 in sections from outlier samples in the Ptch1p53∆E5-
6 and Ptch1p53∆/R172P models, showing the highest Sox2 cluster in Ptch1p53∆E5-6 and the 
most proliferative cluster in Ptch1p53∆/R172P model. Note that frequent Sox2 corresponds 
with low Ki67, and likewise frequent Ki67 corresponds with lower Sox2. Additionally, 
co-localization of p27 and NeuN in adjacent sections demonstrates that NeuN and p27 
often occur along the edges of clusters, whereas proliferative cells occupy the center of 
the cluster. 
Scale, 200 um. Error bars represent Mean + SEM. Unpaired, two-tailed students t-tests 
were used to determine p-values. 
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Figure 22: Impaired p53 Response Permits Enrichment of Proliferative Cells  
following Radiation of Pre-neoplastic Lesions 
(A) H&E images taken from P21-P35 treated P46 mutants from the Ptch1p53∆E5-6, 
Ptch1p53∆/R172P, and Ptch1p53WT models following a long-term IR treatment scheme, in 
which mice were subjected to a 2gray per day dose for a total of 10 days beginning at P21 
and ending at P35. High magnification images Highlight PNLs in the treated brains. 
(B) Quantification of PNL area, in mm2, comparing untreated P22 and P45 (solid bars) 
and P45 following long term IR treatment (striped).  
(B’-B’’’) Enlarged charts of each mutant model show PNL area of Ptch1P53∆E5-6 (B’), 
Ptch1P53∆/R172P (B’’) and Ptch1P53WT (B’’’). 
(C) Immunohistochemistry of P46 PNL treated from P21-P35 for cleaved Caspase-3. 
Inset shows boxed region in high magnification. 
(D) Immunohistochemistry of P46 PNL treated from P21-P35 for Ki67. Inset shows 
boxed region in high magnification.  
(E) Quantification of proliferation in PNLs from the Ptch1p53∆E5-6, Ptch1p53∆/R172P, and 
Ptch1p53WT models in untreated (Solid bars) and treated (Striped bars) mutants at P45. 
Scale, 200 um. Error bars represent Mean + SEM. Unpaired, two-tailed students T-Tests 
were used to determine p-values. 
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Figure 23: Sox2-positive cells in the Ptch1p53∆E5-6/R172P model  represent a treatment-
resistant population 
(A) Co-localization of Sox2 and Ki67 in P46 PNL following P21-P35 treatment 
demonstrating the restored proliferative activity of PNL following prolonged radiation 
treatment. Only 3 of 10 (30%) Ptch1p53WT mice retained proliferative PNL. 
(B) Quantification of the rate of proliferation of the Sox2-positive cell population relative 
to the total Sox2-positive population (Sox2+;Ki67+ / Sox2+) in treated P46 PNLs.  
(C) Co-localization of Sox2 and p53 in P46 PNL following P21-P35 treatment, with 
DAPI as a counterstain.  
(D) Quantification of co-localization frequency of Sox2 and p53. Significantly fewer p53 
positive cells were seen between each model, but no significant difference was found 
between Sox2-positive cell frequency. 
Scale, 200 um. Error bars represent Mean + SEM. Unpaired, two-tailed students t-tests 
were used to determine p-values. 
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Figure 24: Treatment of Pre-neoplastic Lesions Requires Functional p53-mediated 
Apoptotic Response  
(A) Kaplan-Meier survival curve of Ptch1p53∆E5-6, Ptch1p53∆/R172P, Ptch1p53WT and 
Ptch1p53WT/R172P models following the long-term IR treatment scheme.  
(A’)  Table demonstrating Median Survival and Tumor Penetrance of each model. 
(B) Comparison of untreated and treated survival within each mutant model. (p, Log-rank 
(Mantel-Cox) test) 
(C) High magnification H&E images show cellular morphology in MBs arising in the 
Ptch1p53∆E5-6, Ptch1p53∆/R172P, Ptch1p53WT and Ptch1p53WT/R172P models from mice treated 
from P21-P35. 
(D) Low and high magnification immunohisological images demonstrate Ki67 in treated 
Ptch1p53∆E5-6, Ptch1p53∆/R172P, Ptch1p53WT and Ptch1p53WT/R172P models. 
(E) Immunofluorescent co-labeling using anti-Sox2 and anti-Ki67 antibodies on treated 
Ptch1p53∆E5-6, Ptch1p53∆/R172P, Ptch1p53WT and Ptch1p53WT/R172P MB.  
Scale Represents 100 um in high mag images and 1mm in low mag image (D). 
Hematoxylin counterstain was used in DAB staining. DAPI counterstain was used in 
fluorescent images. 
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Figure 25: Radiation Induced Stress Drives Loss of Wild Type p53  
(A) Low and high magnification images of immunohistochemistry images using the anti-
p53 antibody with end-stage MBs treated with the long-term IR treatment of 2gray per 
day dose for a total of 10 days beginning at P21 and ending at P35. Note the inclusion of 
the Ptch1p53WT/R172P model, which differs from the Ptch1p53WT model only after IR 
treatment. 
(B) Genotyping of p53R172P from treated MBs reveal acquired LOH in the Ptch1p53WT/R172P 
model.  
Scale, 200 um. Error bars represent Mean + SEM. Unpaired, two-tailed students T-Tests 
were used to determine p-values. 
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Chapter IV:  Materials and Methods 
4.1 Mouse Models 
Male and female mice carrying a floxed p53 (p53E5-6) allele were maintained on a 
mixed C57Bl6/129Svj genetic background (Wang et. al., 2009). The p53R172P mouse 
strain was backcrossed into C57Bl6 background prior to introduction into the p53 colony, 
where it was crossed into the mixed p53 background. As described previously, the 
hGFAP-Cre mouse (Zhuo et. al., 2001) was initially produced on the FVB background, 
but was backcrossed into the mixed background for greater than five generations prior to 
integration into the p53 colony. The Ptch1+/- model (Goodrich et. al., 1997) was bred into 
and maintained on a mixed C57Bl6/129Svj genetic background prior to crossing into the 
p53E5-6 colony. Control mice from the p53∆E5-6/R172P;hGFAP-Cre-;Ptch1+/- were collected 
and were phenotypically indistinguishable from p53E5-6/E5-6;hGFAP-Cre-Ptch1+/-. 
Littermates were used within experimental procedures as often as possible to minimize 
variance. 
Control and mutant animals were sacrificed either at experimental endpoints, 
specifically postnatal day 8, 22, or 46, or as determined by veterinary assessment. 
Veterinary assessment was focused around brain tumor incidence, as indicated by 
neurological symptoms, including loss of balance, head tilt, ataxia, 
hydrocephalus/macrocephaly, and seizure, with a small portion of mice instead sacrificed 
due to body tumors, typically lymphoma or sarcoma, particularly in germline p53 
models. Control mice were also sacrificed after 350 days if no tumor was in evidence, 
and brains were collected and processed to verify the lack of tumor. Samples were 
collected either by perfusion using phosphate buffered saline followed by 4% 
paraformaldehyde (for paraffin embedding), or collected with a brief perfusion using only 
phosphate buffered saline prior to dissection, with one half the brain frozen using a liquid 
nitrogen bath and the other half brain placed into a 4% paraformaldehyde solution. A 
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subset of control and mutant animals was injected with BrdU, at the concentration of 50 
µg per gram body weight, with 3 injections at 2 hour intervals for mice at postnatal day 
22 and 46 and 5 injections at 2 hour intervals for mice sacrificed due to neurological 
symptoms. BrdU treated animals were sacrificed in the same fashion as untreated animals 
two hours after the final injection. 
Following sacrifice, perfused tissue was processed through a sequence of 
dehydration steps prior to paraffin embedding. Embedded tissue was sectioned sagittally 
at 5 µm thickness, and affixed to Superfrost Plus microscope slides (Fisher Scientific). 
Sections were stained at regular intervals with hematoxylin and eosin stain to allow 
assessment of the MBs arising within the mouse model. Stained slides were assessed for 
the presence of mitotic figures, nuclear molding, and anaplastic cell morphology. 
Additionally, sections were stained by immunohistochemistry to further confirm typical 
MB markers (See below). 
4.2 Irradiation 
Matched littermates with MBs were treated with ionizing radiation using a 
RadSource 2000 with a Mouse Irradiation Fixture and Head Shield (Braintree Scientific 
Inc.), limiting radiation to the head and neck, and received a single dose of 20 Gray 
radiation and collected after 4 hours or a single dose of 4 Gray and collected after 24 
hours. Matched littermates were treated with 2 Gray per Day beginning in their 4th week, 
typically between postnatal day 21 and 23, and received radiation 5 times a week for 2 
weeks. All mice in this study were cared for according to guidelines approved by the 
Animal Care and Use Committee of the University of Michigan as well as the 
Institutional Animal Care and Use Committee of Childrens National Medical Center. 
4.3 Histology, Immunohistochemistry and Immunofluorescence 
Pre-neoplastic lesions were assessed using guidelines established by (Pazzaglia et. 
al., 2006, Mille et. al., 2014). Tumors were classified using the WHO guidebook for MB 
assessment criteria (Louis et. al., 2007). Diagnosis was reached based on hematoxylin 
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and eosin staining, as well as DAB with established MB markers.  
Perfused tissue was dehydrated prior to embedding in paraffin. Parrafin embedded 
tissue was sectioned at 5 um, and adjacent sections were used in immunohistochemistry 
and immunofluorescent analysis. Tissue sections were rehydrated by sequential treatment 
with xylene, ethanol and water, prior to an eight minute antigen retrival using Retrieve-
All antigen unmasking system (Covance) heated in coplin jars. Following retrieval, tissue 
was permeabalized using triton X-100 and then blocked with 3.5% goat or donkey serum, 
depending on antibody selection. For immunohistochemistry, blocked tissue was was 
incubated with primary antibody overnight at 4°C, prior to application of alkaline-
phosphatase secondary antibody (Vector) at 1:400 dilution for 1 hour at room 
temperature. Following secondary antibody, the Avidin/Biotin Complex peroxidase 
system was used for 30 minutes. Following this, DAB was applied and slides were 
counterstained with nuclear marker hematoxylin. For immuno-fluorescent procedures, 
blocked tissue was incubated with primary antibody overnight at 4°C, prior to application 
of fluorescence conjugated secondary antibody, either Alexa488, Alexa555 or Alexa647 
(Invtirogen), at 1:400 concentration for 1 hour at room temperature. Slides were 
counterstained with DAPI, and imaged using a fluorescent microscope. 
Immunofluorescent quantification was assayed by imaging multiple tumor regions, 
whereas DAB quantification was assessed in high magnification images and 
supplemented with automatic quantification using ImageJ. Whole mount images of 
perfused brains were taken using a dissection microscope (Olympus) with a variable 
objective on a solid background, using an integrated ruler to maintain scale. Brains were 
imaged in multiple orientations, with the medial brain used to assess cerebellar area. Pre-
neoplastic lesion volume was assessed based on multiple H&E stained sections at 200-
micrometer intervals. 
The following primary antibodies were used: 
p53-CM5 (1:500, rabbit, Leica, p53-CM5P-L) 
Sox2 (1:200, goat, Santa Cruz, SC-17320) 
BLBP (1:500, rabbit, AbCam, AB-32423) 
NeuN (1:500, mouse, Millipore, MAB-377) 
Nestin (1:100, mouse, Millipore, MAB-353) 
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Cleaved Caspase-3 (1:500, rabbit, Cell Signaling, 9661S) 
Ki-67 (1:500, rabbit, Abcam, AB15580) 
Ki-67 (1:500, mouse, BD, 550609) 
BrdU (1:500, rat, Abcam, AB-6326) 
p27 (1:500, mouse, BD, 610242) 
Olig2 (1:2,000, rabbit, Millipore, AB-9610) 
GFAP (1:1,000, rabbit, Dako, Z0334) 
Synaptophysin (1:200, rabbit, Covance, SIG-3261) 
p21 (1:200, mouse, BD, 556430) 
4.4 TP53-DNA Structure, Plasmid Construction, Cell Culture, Transfection and Co-
immunoprecipitation for Mutant P53 Analysis 
Structure of TP53DBD-DNA complex was based upon the published crystal 
structure of the TP53DBD-DNA complex (Cho et. al., 1994; Kitayner et. al., 2006). Each 
of the TP53/p53 deletions and mutations used in this study was labeled in the structure of 
TP53DBD-DNA complex. Plasmids containing full-length human wild type p53 (pC53-
SN3) and MDM2 were gifts from Dr. Yi Sun’s lab at University of Michigan, Ann Arbor. 
The full length of wild type TP53, TP53R175H, TP53 inframe deletion of Exon 5 and 6 
(human TP53 version of p53Δ5-6) and TP53 in-frame deletion of Exon 5 to 8 
(p53ΔDBD with no the DNA-Binding Domain [DBD]) were amplified by PCR and 
reconstructed into pCDNA3.1/Flag-His vector (Invitrogen, Carlsbad, CA, USA). The 
full-length of mouse Mdm2 was amplified from mouse MEF cells with primers:  
Forward 5' ATGTGCAATACCAAC 3'  
Reverse 5' AGTTGAAGTAAGTTAGCAC 3' 
 
Mdm2 was recombined into pLentilox RSV GFP vector (Core facility of 
University of Michigan). p53-specific siRNA(s) or mismatched siRNA oligos were 
constructed into lentiviral vector with H1 promoter (gifts from Dr. Yi Sun’s lab). The 
targeting sequences chosen for mouse p53 (NM_011640.3) mRNA are:  
GTACATGTGTAATAGCTCC (Sequence 1),  
CAGTCTACTTCCCGCCATA (Sequence 2) and  
GTAGATGTCTAATAGCTGC (mismatch siRNA).  
Mouse p53 siRNA sequence 1 is from a previously published paper (Dirac and 
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Bernards, 2003); sequence 2 is from RANi Codex (http://cancan.cshl.edu/cgi-
bin/Codex/Codex.cgi). All plasmids were verified by targeted Sanger sequencing. 
HEK293T and HCT116 TP53-/- human cell lines were grown in DMEM containing 10% 
FBS, 100U/ml penicillin, and 100ug/ml streptomycin at 37oC in 5% CO2. Transfection 
was performed with SuperFect transfection reagent (Qiagen) and lentivirus was produced 
by co-transfecting individual plasmids together with pCMVΔR8.9 and pVSV-G plasmids 
into HEK293T cells. For coimmunoprecipitation assay, HEK293T cells were co-
transfected with indicated plasmids. Single transfection with one of the plasmids alone 
was used as control. 24 hours later, cells were harvested and lysed on ice using 500ul 
lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA PH 8.0, 0.5% NP40) 
in the presence of protease inhibitors. The detergent-soluble fraction was recovered by 
centrifugation at 4oC for 20 min at 12000 rpm and the supernatants were subjected to 
immunoprecipitation. 400ul of the supernatant was incubated with mouse anti-Flag 
antibody (M2, Sigma-Aldrich) and protein G PLUS-Agarose beads (Santa Cruz) with 
gentle rotation at 4oC for 4 hours. The beads were washed four times with lysis buffer 
and precipitates were eluted with 2XSDS-PAGE sample buffer and analyzed by Western 
blotting. 
4.5 Western Blot 
Snap-frozen tissue samples from wild type control brains and tumors were 
homogenized in Pierce RIPA Buffer (Thermo Scientific) (10 μl buffer/1 mg tissue), 
mixed 1:1 with Laemmli Sample Buffer (BioRad) and boiled at 100°C for 8 minutes.  
Samples were then subjected to SDS-PAGE using the Criterion TGX Precast gels 
(BioRad) and transferred onto PVDF membranes (Millipore). The membranes were 
blocked in 5% non-fat milk prepared in TBST and prior to an overnight incubation with 
primary antibodies at 4°C. Next the membranes were washed with TBST and incubated 
in horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature 
for 1 hour. Signal was detected using Pierce ECL Western Blotting Substrate (Thermo 
Scientific). The primary antibodies used in this study were as follows:  
p53 (1:1000, rabbit, Leica, p53-CM5P-L) 
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M2/Anti-Flag (1:1000, mouse, Sigma, F3165)  
GFP (1:3000, rabbit, Santa Cruz, SC-8334) 
MDM2 (1:500, mouse, (Xiufang et. al., 2014)) 
p21 (1:500, mouse, BD, 556430) 
β-Actin (1:5,000-10,000, mouse, Sigma-Aldrich, A-5441) 
 
HRP-conjugated secondary antibodies were: anti-mouse (1:5,000-1:10,000, goat, BioRad, 
170-6516) and anti-rabbit (1:5,000-1:10,000, goat, BioRad, 170-6515).  
4.6 Genotyping 
Genetic analysis of mice in the colony used genomic DNA extracted from P18-
P21 tail snips incubated overnight at 50°C in SDS-EDTA TAE Buffer plus Proteinase K, 
prior to mixing the resultant solution with 70% isopropanol (1:1), allowing DNA to 
precipitate. Precipitate was then transferred and diluted into ultrapure water prior to PCR 
analysis for the Cre insert, p53 loxP recombination, p53R172P, and the Ptch1 knockout 
allele using the Taq 2X MeanGreen Master Mix (Empyrical BioScience) in conjuncture 
with the following primers: 
p53R172P 
p53R172PA 5- ACCTGTAGCTCCAGCACTGG -3 
p53R172PB 5- ACAAGCCGAGTAACGATCAGG -3 
p53 flox 
p53.i6 5 - GCTGCAGGTCACCTGTAG - 3 
p53.e7 5- CATGCAGGAGCTATTACACA -3 
p53.e4 5- TGGGACAGCCAAGTCTGTTA -3  
hGFAP-Cre 
ICres 5- CCGTTTGCCGGTCGTGGG -3 
ICreas 5- CGTATATCCTGGCAGCGATC -3 
Ptch1 
PtcNeoF3 5- TGGGGTGGGATTAGATAAATGCC -3 
PtcR3 5- TGTCTGTGTGTGCTCCTGAATCAC -3  
4.7 Sequencing 
Total RNA was isolated from MBs arising within the Ptch1, Ptch1p53, and 
Ptch1p53 mutants, as well as control cerebellum from both WT and Ptch1p53WT mice, 
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by means of the RNEasy kit (Qiagen), as well as the AllPrep DNA/RNA Mini Kit 
(Qiagen). cDNA synthesis was performed using QuantiTect Reverse Transcription Kit 
(Qiagen). The cDNA product, following quality assessment and measurement of 
concentration, were used to sequence exons of the p53 allele. The p53 normal and mutant 
transcripts, encoding the entire open reading frame, was amplified with primers 1 and 2, 
purified, and sequenced. To improve sequence quality, shorter product was prepared 
combining primers 1 and 4, 3 and 8, and 7 and 2, which were amplified, purified and 
sequenced as well. Additionally, exons comprising the p53 DNA-binding domain (E4-8) 
were analyzed using genomic DNA specific to individual exons. cDNA sequencing 
primers are listed below: 
P1,   5’- AGGTAGCGACTACAGTTAGGGG -3' 
P2,   5’- TGAAGTCATAAGACAGCAAGGAG -3' 
P3,   5’- CCTGCCATCACCTCAC -3' 
P4,  5’- GGAAGCCATAGTTGCC -3' 
P5,   5’-TCTGTTATGTGCACGTACTC -3' 
P6,   5’- CGGGTGGCTCATAAGG -3' 
P7,   5’- GCCGGCTCTGAGTATA -3' 
P8,   5’- TGTGATGATGGTAAGGA -3' 
Sequencing primers used with genomic DNA are listed below: 
p53.E4F 5'- GCTGGTAGGCTGAGAACACA -3' 
p53.E4R 5'- ACAGGCTGAAGAGGAACCCC -3' 
p53.E5F 5'- CCTTGACACCTGATCGTTAC -3' 
p53.E5R 5'- GAGCAAGAATAAGTCAGAAGC -3' 
p53.E6F 5'- ACTGGCAGCCTCCCATCTT(C)C -3' 
p53.E6R 5'- CTAGAAAGTCAACATCAGTC -3' 
p53.E7F 5'- CTAGACTGATGTTGACTTTC -3' 
p53.E7R 5'- CTGGGGAAGAAACAGGCTAA -3' 
p53.E8F 5'- CTTGTGCTGGTCCTTTTCTTG -3' 
p53.E8R 5'- GAGGTGACTTTGGGGTGAAG -3' 
4.8 Quantitative RT-PCR 
Both RNAs and genomic DNAs were extracted from cell lines, control tissues and 
MBs using the AllPrep DNA/RNA Mini Kit (Qiagen). cDNA for RT-PCR was generated 
through the QuantiTect Reverse Transcription Kit (Qiagen).. QuantiTect SYBR green 
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Master Mix (Qiagen), and all PCR experiments were conducted using Applied 
Biosystems 7500 Real-Time PCR System. Results were analyzed using ∆CT between 
targets and were quantified through a standard curve based method; each sample was run 
in triplicate and normalized to the expression of the housekeeping gene GADPH. The 
following primers were used for quantitative reverse transcriptase PCR (qRT-PCR): 
p21  
5’ CACAGCTCAGTGGACTGGAA 3’ 
5’ ACCCTAGACCCACAATGCAG 3’ 
Puma   
5’ GCGGCGGAGACAAGAAGA 3’ 
5’ AGTCCCATGAAGAGATTGTACATGAC 3’ 
Gli1  
5’ GCTCCGCAAACACGTGAAGA 3’ 
5’ GCCGGATCCTCCTTCCCTTT 3’ 
Gli2  
5’ TCTAGTCCACGTGTGACCCC 3’ 
5’ AGGTCCGAATCATGCGTTGT 3’ 
N-Myc  
5’ AGGAAGCACTCCCCCATATT 3’ 
5’ CCGCCGAAGTAGAAGTCATC 3’ 
Gapdh  
5’ ACCCAGAAGACTGTGGATGG 3’ 
5’ CACATTGGGGGTAGGAACAC 3’ 
4.9 Cell Culture and Chromosome Assay 
Primary cell cultures were isolated from malignant tumor taken from untreated 
mice when mice showed neurological symptoms. MBs were rinsed in 4ºC PBS prior to 
dissection, and tissue was then transferred into chilled DMEM medium. Tissue was 
gently minced prior to enzymatic cell dissociation using 37ºC Accutase (Innovative Cell 
Technologies). Following digestion, cells were transferred to serum-free self-renewal 
medium (Molofsky et al., 2003). Cells were fed with fresh media ever 3-5 days and 
passaged every 1-2 weeks, based on observed growth rate, with cells plated onto 6-well 
ultra-low attachment surface polystyrene plates (Corning). Excess cells were frozen using 
liquid nitrogen storage. 
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Chromosome analyses were conducted using primary cell lines based on a 
karyotyping protocol provided by Dr. David Ferguson’s laboratory (Ferguson et al., 
2000). Following splitting, cells at or below two passages were allowed to recover for 24 
hours prior to incubation with Colcemid (KaryoMax, Gibco, Life Technologies) for 1 
hour to arrest proliferation at metaphase. Cells were then incubated in 37°C 0.4% KCl 
prior to fixation in 4°C Methanol:Glacial acetic acid (3:1) fixative overnight. Fixed cells 
were dropped onto Superfrost Plus microscope slides (Fisher Scientific), and then stained 
with DAPI. Chromosomes of metaphase cells were analyzed. 
4.10 Statistics 
Kaplan-Meier survival curves were prepared using Prism, and included mice 
sacrificed due to brain tumor, body tumor and veterinary concerns, as well as aged 
control mice, and compared using the Mantel-Cox test. Histology and whole mount area 
quantification was determined using ImageJ (NIH). Cell number was counted manually 
and verified with ImageJ cell counter. Whenever possible, quantification was conducted 
using multiple replicates taken from discrete regions of the brain as well as multiple 
sections when possible. Student’s 2-tailed t-test was used for the comparison of areas, 
cell numbers and staining frequency. Data were presented as Mean +/- Standard Error of 
the Mean (SEM), and p < 0.05 was considered to be statistically significant. 
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Chapter V: Discussion and Future Directions 
The objective of my thesis project is to understand how most MBs are capable of 
forming without requiring inactivation of the p53 pathway, despite the fact that 
individuals with Li-Fraumeni syndrome carrying TP53 mutations have an increased risk 
of developing SHH-MBs. In this thesis, I used two mutant p53 alleles to identify two 
populations of GCPs with differential sensitivity to p53-pathway activation, 
corresponding with p53-activation sensitive and resistant GCPs (Figure 26). In 
identifying the GCP population(s) sensitive to p53-pathway activation, I show that this 
type of GCP is effectively protected by a robust and sustained p53-mediated apoptotic 
response, and appear to form SHH-MBs only when TP53 mutations occur as an early 
event in the context of Li-Fraumeni patients with germline TP53 mutations. Despite a 
robust p53-mediated apoptotic response, a subset of GCPs forms SHH-MBs without 
disrupting the p53 pathway. This type of GCP appears to be resistant to p53-pathway 
activation upon oncogenic stress by Ptch1 loss, and thus do not present selective pressure 
to disrupt p53 during tumorigenesis. The concept of differential p53-pathway activation 
within GCPs offers a compelling model explaining how SHH-MBs may show increased 
incidence in germline mutant TP53 individuals but rarely acquire somatic mutations to 
TP53 (Pazzaglia et. al., 2006, Kool et. al., 2014).  
5.1 p53-activation sensitive GCPs during cerebellar development  
All SHH-MBs with germline TP53 mutations arose during childhood (ages 4 - 
17), suggesting that p53 may play a role in regulating cerebellar stem and progenitor 
cells, including GCPs, the cell(s) of origin for SHH-MBs (Rausch et. al., 2012, Northcott 
et. al., 2012, Kool et. al., 2014). Despite the increased SHH-MB incidence associated 
with germline TP53 mutation, studies using germline p53 mutation produced no overt 
defects in the cerebellum (Donehower et. al., 1992, Jacks et. al., 1994). Likewise, p53 
conditional inactivation mutants, although capable of promoting SHH-MB with low 
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penetrance, typically did not feature cerebellar defects, suggesting that p53 is not required 
for proper cerebellar development (Wang et. al, 2009). However, when p53 is hyper-
activated, such as in the Mdm2puro/∆E7-9 mutant - producing 70% less Mdm2 protein – it 
was observed that the size of the developing EGL was reduced, and that the Ptch1+/-
;Mdm2puro/∆E7-9 model produced no PNLs (Malek et. al., 2011). These p53 gain-of-function 
studies suggest that p53 activation is normally a tightly constrained process in GCPs, 
limited by the inherent p53-Mdm2 negative feedback loop but capable of potent response 
when de-repressed. Using p53∆E5-6 as a marker for p53 activation, I identified a population 
of rare p53-actvating GCPs comprising less than 1% of the highly proliferative outer 
EGL. Surprisingly, in spite of the lack of p53-pathway activation, only 50% of p53∆E5-6-
positive GCPs were proliferative compared to the 90% frequency observed in 
surrounding outer EGL, suggesting that cells undergoing stress-activated p53 as well as a 
p53 independent cell-cycle arrest function. Introduction of even a single allele of p53R172P 
was capable of reducing p53-positive cells by more than 75%, showing that a p53-
activation sensitive GCP population exists during development and will be rapidly 
targeted by p53 activation. As MBs occur at low frequency in the p53∆/∆E5-6 model (Wang 
et. al., 2009), it is likely that the p53-activation sensitive population has the potential to 
give rise to SHH-MBs, suggesting that p53-pathway activation eliminates tumorigenic 
cells. Thus, p53-sensitive GCPs that would typically be eliminated through p53-pathway 
activation are capable of undergoing oncogenic transformation and becoming MBs, 
mirroring the increased frequency for SHH-MBs in Li-Fraumeni patients (Zhukova et al. 
2013; Kool et al. 2014). Overall, these results show that a rare GCP population activates 
p53 during cerebellar development, but this population is tightly regulated by the Mdm2-
p53 negative feedback loop. Even with the introduction of mutant p53∆E5-6, a p53-
independent cell-cycle arrest mechanism(s) targets these p53-positive GCPs, explaining 
why previous studies have not detected these p53 positive cells during cerebellar 
development. 
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5.2 p53-activation sensitive GCPs and SHH-MB formation 
In the developing cerebellum, I observed a proliferative GCP population that 
would accumulate p53∆E5-6. One of the novel findings of this study was identification of 
p53∆E5-6-positive cluster in the P8 EGL following loss of Ptch1, potentially representing 
the earliest detectable MB-precursor cells. Although located amongst a highly 
proliferative population, the p53∆E5-6-clusters possessed several traits demonstrating 
abnormal behavior, including disruption of the boundary between outer and inner EGL 
and failure to undergo neuronal differentiation. Unlike many p53 positive cells in the 
outer EGL, the p53∆E5,6-positive cells within clusters remained highly proliferative, 
comparable to the normal proliferative rate observed in GCPs of the adjacent outer EGL. 
Curiously, the majority of these p53∆E5-6-positive clusters were Sox2-positive, a marker 
typically associated with cerebellar stem cells, suggesting that GCPs de-differentiate and 
acquire stem-like characteristics during an oncogenic transformation event (Oliver et. al., 
2005, Ahlfeld et. al., 2013). Hyperactive SHH pathway activation has been shown to lead 
to increased Sox2 expression (Ahlfeld et. al. 2013), potentially indicating that Ptch1 loss, 
previously suggested as an early event in SHH-MB initiation (Tamayo-Orrego et. al., 
2016), may be a trigger leading to GCP de-differentiation into Sox2-positive stem-like 
cells. Just as frequent p53∆E5-6 accumulation was noted in GCPs, both PNLs and SHH-
MBs produced in the Ptch1p53∆/∆E5-6 model maintained a high frequency of p53 positive 
cells throughout MB progression, demonstrating that stress would likely eliminate these 
cells if p53 activity had not already been lost. In turn, the Ptch1p53∆/∆E5-6 model is capable 
of rapid MB induction, which is only possible when p53 activity is completely lost – 
demonstrated by the 38% increase in median survival following introduction of a single 
p53R172P hypomorph allele. These results demonstrate the presence of a p53-activation 
sensitive population of GCPs that are effectively protected from tumorigenesis by a 
robust p53-mediated apoptotic response during cerebellar development. Only when p53 
is inactivated as an early event, analogous to the context of Li-Fraumeni syndrome, it is 
possible for these p53-activation sensitive GCPs to progress to form SHH-MBs (Zhukova 
et al. 2013; Kool et al. 2014). 
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5.3 p53-activation resistant GCPs during cerebellar development 
Although functional p53 was able to reduce SHH-MB penetrance, I still observed 
a 36% tumor penetrance in the Ptch1p53WT model. These tumors formed without 
requiring mutation of p53 and retained the ability for the p53 pathway to activate 
following genotoxic stress. The presence of a functional p53 response demonstrates that 
SHH-MBs are capable of forming without requiring p53 pathway inactivation, although it 
is possible that they have acquired p53-pathway alterations sufficient to limit pathway 
activation (Wasylishen and Lozano 2016). The formation of SHH-MBs without p53 
pathway inactivation suggests the existence of a p53-activation resistant population of 
GCPs during cerebellar development. These GCPs, in spite of oncogenic stress induced 
by Ptch1 loss, are not put under selective pressure sufficient to necessitate complete 
inactivation of the p53 pathway. Based on these observations, I predicted that p53-
activation resistant cell populations would be present in all Ptch1+/- mice. In support of 
this idea, PNLs of the Ptch1+/-p53∆E5-6/∆E5-6 and Ptch1+/-p53∆E5-6/R172P models consisted of a 
high p53 and low p53 variant, which I attribute its cell of origin to p53-activation 
sensitive and resistant GCPs, respectively. The concept of distinct GCP populations with 
differential sensitivity to p53-pathway activation has previously been proposed, when it 
was demonstrated that GCPs at P0.5 had minimal response to radiation, whereas GCPs at 
P10 were radiation sensitive, eliciting a strong p53-mediated apoptotic response 
(Pazzaglia et. al., 2006). Further, irradiation was capable of inducing increased SHH-MB 
incidence if P0.5 cerebellum was stressed while causing a decrease in incidence when 
P10 cerebellum was treated (Pazzaglia et. al., 2002). The existence of distinct temporal 
windows for GCP to respond to p53 was demonstrated in a CRISPR/CAS9 model, where 
embryonic inactivation of Ptch1 lead to SHH-MB initiation regardless of p53 function, 
but postnatal Ptch1 inactivation could only produce widespread SHH-MBs when p53 was 
also inactivated (Zuckermann et. al. 2015). Likewise, differential times of Ptch1  Math1-
CreER/Ptch1flox/flox These studies and my observations suggest the existence of a p53-
activation resistant GCP population capable of producing SHH-MBs, and suggests that 
this GCP population may possess inherent differences from p53-activation sensitive 
GCPs that correspond with differences in p53 activity between early and late GCPs. 
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These observations seem to support my initial model, showing that there are two paths 
capable of giving rise to SHH-MB. Along one path, p53-activation sensitive GCPs would 
be eliminated unless TP53 mutation occurs in the germline or early development. 
However, SHH-MBs forming on this path represents a highly aggressive SHH-MB 
variant, with reduced treatment response and a higher degree of genomic instability 
(Northcott et. al., 2012, Zhukova et. al., 2013, Kool et. al., 2014). The other path contains 
SHH-MBs that form from a p53-activation resistant population, which never undergo 
sufficient selective pressure to necessitate the loss of wild type p53, and therefore are 
capable of a p53-mediated response to treatment. 
5.4 A connection between p53-activation resistant GCPs and Sox2-positive cells 
Previous studies have identified that Sox2-positive cells are a stem-like 
population in SHH-MBs capable of resisting chemotherapy and inducing recurrence 
(Ahlfeld et. al., 2013, Vanner et. al., 2014). My results demonstrate that Sox2-positive 
cells were present in PNLs and SHH-MBs, and that these cells are resistant to p53-
pathway activation, with less than 10% of Sox2-positive stem-like cells expressing 
p53∆E5-6, thereby providing a mechanism explaining the observed resistance to radiation 
and chemotherapy (Vanner et. al., 2014). Even following high dose radiation, only 30-
40% of Sox2-positive cells were found to stabilize p53, demonstrating that, even upon 
induced genotoxic stress, Sox2-positve cells are still relatively resistant to p53-pathway 
activation. Infrequent activation of p53 in Sox2-positive cells suggests that these cells 
may represent a potential source for p53-activation resistant SHH-MBs. One of the 
common theories surrounding stem-like cells in human cancer is that these cells are able 
to survive therapy and initiate recurrent disease (Vanner et. al., 2014). Activation of p53 
by radiation during SHH-MB progression produced a differential response between 
Sox2-positive and Sox2-negative cells. Within both the Ptch1p53R172P and Ptch1p53WT 
models, activation of p53-mediated cell cycle arrest robustly drove Sox2-negative cells 
out of the cell cycle and induced neuronal differentiation. However, only in models 
retaining wild type p53 activity was it possible to eliminate Sox2-positive cells and 
reduce the incidence of SHH-MBs. These data explain that the treatment resistance 
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observed in Sox2-positive cells is likely a result of constrained p53-response, although 
how the p53 response is constrained in these cells requires additional study.  Further, this 
treatment was sufficient to put a selective pressure on developing SHH-MBs, leading to 
the loss of the p53WT allele in SHH-MBs from the Ptch1+/-p53WT/R172P model. These 
observations match with recurrent human MBs, which frequently gain mutations to TP53 
(Hill et. al., 2015, Morrissy et. al. 2016). 
5.5 Differential roles of p53 signaling in SHH-MB progression and treatment 
Following cerebellar development, the EGL is depopulated with GCPs migrating 
to the IGL, but hyper-activation of the SHH pathway interferes with this process, leading 
to the formation of PNLs (Oliver et. al., 2005). A recent study from the Charron lab 
suggested that SHH-MB initiation and progression are primarily hindered by the p53-
mediated senescence response (Tamayo-Orrego et. al., 2016). In this study, the Ptch1+/- 
model was used to demonstrate enrichment of cell-cycle arrest/senescence proteins P21 
and P16Ink4A in PNLs but not in SHH-MBs, which was taken as evidence that these SHH-
MBs overcame the senescence response that had limited their progression into tumor 
(Tamayo-Orrego et. al., 2016). Using my mutant p53 models, I show that, in comparison 
Ptch1+/-p53WT/WT, the Ptch1+/-p53R172P model, which losses p53-mediated apoptotic 
response, contains a four-fold increase in the number of PNLs observed after cerebellar 
maturation, suggesting that activation of p53 mediated apoptosis is a crucial barrier for 
p53-activation sensitive GCPs. Radiation treatment of PNLs led to p53-mediated cell-
cycle arrest and differentiation, although it was insufficient to remove Sox2-positive 
cells. This suggests that activation of the p53-mediated senescence response is capable of 
limiting SHH-MB progression but was incapable of targeting Sox2-positive cells. As 
such, although senescence response may play a role in removing cells during GCP 
progression, my data demonstrates that successfully targeting PNLs requires the retention 
of the p53-mediated apoptotic response, thereby suggesting that p53-mediated 
senescence, while capable of limiting tumor progression, is not the mechanism by which 
p53 prevents SHH-MB occurrence.  
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Just as p53-mediated apoptosis was crucial to remove GCPs, so too was the p53 
apoptotic response crucial for SHH-MB treatment. Using a SmoM2;Math1-Cre mouse in 
conjunction with either conditional deletion of p53 or Bax, the gene encoding p53 
apoptotic effector Bax, it was shown that the radiation response of SHH-MBs is highly 
dependent on p53-mediated apoptotic response (Crowther et. al., 2016). Similarly, I 
found that when p53 activation was enhanced with radiation, only a complete wild type 
p53 response was capable of successfully eliminating SHH-MB. Although many PNL 
cells were removed through p53-mediated cell-cycle arrest by activation of p53R172P, this 
was insufficient to target a highly aggressive compartment of cells, which remained 
capable of producing SHH-MBs in spite of treatment. These findings provide evidence 
that, unlike most tumors where chemotherapy and radiation response is p53 pathway 
independent, SHH-MB treatment response is reliant on retained p53 function. This 
concurs with in vitro and in vivo data showing that activation of the p53 response by 
MDM2 inhibitor Nutlin-3 provided a potent suppressive effect on SHH-MBs (Kunkele et. 
al., 2012). This could also hold true for other cancers without mutant TP53, such as 
pediatric low-grade glioma. My study provides a clear association between p53 mutation 
and treatment response, showing that the apoptotic effects of radiation treatment in SHH-
MBs are almost entirely p53-pathway dependent. 
5.6 Future Directions 
My model shows that two paths lead to the formation of SHH-MB, a p53-
activation sensitive GCP population that form SHH-MBs in the context of Li-Fraumeni 
syndrome with germline TP53 mutations (otherwise it would be eliminated by p53-
mediated apoptosis during cerebellar development), and a p53-activation resistant GCP 
population that form SHH-MBs without selective pressure to disrupt the p53 pathway. 
This model opens up several potential future directions for the project: 1) I demonstrate 
that two distinct populations of GCPs, differential sensitivity to p53 activation, can give 
rise to SHH-MB, but do not understand the mechanism by which p53-resistant GCPs 
evade p53 upon oncogenic stress. 2) I have found Sox2-positive cells during different 
stages of SHH-MBs, and observed distinct characteristics between the behavior of these 
  112 
cells, shifting from highly proliferative cells at early stages to quiescent cells in PNLs and 
SHH-MBs. It is unknown if these cells represent the same cell types, nor how they relate 
to neural stem and progenitor cells during cerebellar development.  
My current data provide evidence for differential sensitivity in the p53-pathway 
activation in GCPs, but the mechanism(s) underlying differential p53-pathway activation 
remain unknown. Using p53∆E5-6 as a marker, I will investigate the sensitivity of p53-
pathway activation in distinct GCP populations during different stages of cerebellar 
development upon radiation-induced DNA damage or inducible Ptch1 loss. I will 
compare treated and untreated GCPs at P0.5 and P8, and demonstrate if p53∆E5-6 is 
accumulated in these GCPs. I expect that p53∆E5-6 will not accumulate in P0.5 GCPs, but 
in P8 or later GCPs, and will characterize cells that activate p53. If p53 accumulation is 
observed in these mutants, I will then attempt to characterize the behavior and markers 
associated with p53∆E5-6 positive GCPs. Characterizing these GCP populations may give 
insight into distinct cells of origin for p53-activation sensitive and resistant SHH-MBs.  
I have identified three distinct populations of Sox2-positive cells during SHH-MB 
initiation and progression, a proliferative GCP-like cell, a quiescent SHH-MB stem-like 
cell, and a proliferative population of Sox2-positive cells observed in the radiation treated 
Ptch1p53R172P model. Previous studies have emphasized that Sox2-positve cells are a 
quiescent, stem-like population that are highly resistant to chemotherapy and radiation 
(Oliver et. al., 2005, Hambardzumyan et. al., 2008, Ahlfeld et. al., 2013, Vanner et. al., 
2014). However, the relationship between these different Sox2-positive cell populations, 
as well as their similarity to Sox2-positive stem cells, remains uncertain. To address this 
question, I will introduce the Sox2-GFP allele into my current Ptch1p53 models to isolate 
each of these Sox2-positive populations, either using flow sorting or laser capture micro-
dissection (Arnold et. al., 2011, Vanner et. al., 2014). By comparing the expression 
pattern of the Sox2-positive cell populations, I will be able to determine whether these 
are truly distinct cells, or if they are instead the same cell type responding to distinct 
environmental stimuli. Further, comparison of these cells to Sox2-positive stem cells will 
demonstrate whether they maintain a stem-like expression pattern and may provide hints 
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as to how these cells remain quiescent. Better understanding of the Sox2-positive cell 
populations during different stages of SHH-MB development may have implications for 
therapeutic approach, as these cells have been implicated as a key mechanism of SHH-
MB recurrence. 
5.7 Summary 
In summary, I showed that SHH-MBs arise from at least two distinct GCP 
populations during cerebellar development, a p53-activation sensitive and resistant GCP. 
I demonstrate that a sustained p53-mediated apoptotic response is capable of eliminating 
p53-activation sensitive GCPs, which are only able to form SHH-MB when TP53 
mutation occurs as an early event such as germline mutations associated with Li-
Fraumeni syndrome. These GCPs with p53 activation formed the earliest detectable 
PNLs, and gave rise to highly aggressive p53-mutant SHH-MBs. However, a population 
of p53-activation resistant GCPs was capable of forming p53-wild type SHH-MBs, which 
were effectively targeted by p53-mediated apoptosis following radiation treatment. By 
using radiation to enhance p53-mediated responses on developing PNLs, I showed that 
wild type p53 activation is capable of eliminating SHH-MBs, but this selective pressure 
led to the loss of wild type p53 in Ptch1+/-p53WT/R172P mutants, recapitulating human 
recurrent MB. Of translational significance, I demonstrated the mutational status of p53 is 
of critical importance to predict treatment response of SHH-MBs. Further study of the 
characteristics of p53-activation sensitive and resistant GCPs may provide novel 
therapeutic approaches to the treatment of different types of SHH-MBs. 
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Figure 26: Proposed Model of p53 activation in cerebellar development and SHH-
MB 
Graphic illustration of p53-activation sensitivity in developing cerebellum. Early 
postnatal day 0.5 (P0.5) granule cell precursors (GCPs) are p53-activation resistant, 
whereas late postnatal day 10 (P10) GCPs are p53-activation sensitive. If p53 raises 
above a critical threshold, cells will be eliminated by selective pressure unless they 
mutate p53.  
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